実践　臨床生殖免疫学

出版社： 中外医学社
著者：
発行日： 2018-05-25
分野： 臨床医学：外科  >  産婦人科学
ISBN： 9784498060883
電子書籍版： 2018-05-25 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

12,100 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

12,100 円(税込)

購入する

商品紹介

独学での攻略が難しい免疫学をやさしく解説。各領域のトップランナーが集結した生殖免疫学のバイブル。

目次

  • I　総　論
    　1　生殖免疫学を理解するために
    　　1　免疫学の必須基礎知識
    　　2　腫瘍免疫
    　　3　感染免疫
    　　4　移植免疫
    　　5　自己免疫疾患と妊娠
    　　6　受精と免疫
    　　7　免疫が関与する不妊症─最近の話題から─
    　　8　免疫学的妊娠維持機構
    　　9　免疫が関係する流産
    　　10　免疫が関係する早産
    　　11　免疫が関係する妊娠高血圧症候群
    　　12　免疫システムと陣痛発来
    　　13　母体から胎児への免疫の移行
    　　14　子宮内膜症と免疫

    II　各論
    　1　女性不妊症・ARTと免疫
    　2　男性不妊症と免疫
    　3　子宮内膜症と免疫
    　4　不育症と免疫
    　5　妊娠と免疫
    　6　感染症と免疫
    　7　腫瘍免疫
    　8　移植免疫
    　9　ワクチン
    　10　治療経験

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.21 掲載の参考文献
1) Abbas AK, Lichtman AH, Pillai S, editors. Innate Immunity. In : Cellular and Molecular Immunology, 8th ed. Philadelphia : ELSEVIER ; 2014. p.51-86.
 
2) 熊ノ郷淳, 阪口薫雄, 竹田潔, 他, 編. 免疫学コア講義 改訂4版. 東京 : 南山堂 ; 2017. p.129.
 
3) Abbas AK, Lichtman AH, Pillai S, editors. Effector Mechanisms of Humoral Immunity. In : Cellular and Molecular Immunology, 9th ed. Philadelphia : ELSEVIER ; 2018. p.275-98.
 
4) Spits H, Artis D, Colonna M, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol. 2013 ; 13 : 145-9.
 
5) Abbas AK, Lichtman AH, Pillai S, editors. Specialized Immunity at epithelial barriers and in immune privileged tissue. In : Cellular and Molecular Immunology, 9th ed. philadelphia : ELSEVIER ; 2018. p.299-324.
 
6) Abbas AB, Lichtman AH, Pillai S. editors. Immunologic Tolerance and Autoimmunity : Cellular and Molecular Immunology, 9th ed. philadelphia : ELSEVIER ; 2018. p.325-50.
 
P.32 掲載の参考文献
1) Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011 ; 480 : 480-9.
 
2) Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature. 1987 ; 328 : 267-70.
 
3) Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 ; 11 : 3887-95.
PubMed
4) Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015 ; 33 : 4015-22.
PubMed
5) Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007 ; 104 : 3360-5.
 
P.46 掲載の参考文献
1) Abbas AK. Lichtman AH, Pillai S. Cellular and Molecular Immunology, 9th. Philadelphia : Elserier ; 2017.
 
2) Playfair J, Bancroft G. Infection & Immunity, 4th ed. Oxford : Oxford University Press ; 2013
 
3) 清野宏, 編. 臨床粘膜免疫学東京 : シナジー ; 2011.
 
4) 小安重夫, 野本明男, 光山正雄, 他. 免疫・感染生物学. 東京 : 岩波書店 ; 2011.
 
5) Nature Reviews of Immunology. <http://www.nature.com/nri/index.html?foxtrotcallback=true>
 
6) Nature Reviews of Microbiology. <http://www.nature.com/nrmicro/index.html>
 
P.59 掲載の参考文献
1) 小川公明. HLAの基礎知識 2. MHC. 2016 ; 23 : 185-92.
 
2) 寺岡慧. 腎移植の免疫反応. In : 腎移植の全て. 高橋公太, 編. メジカルビュー社, 東京 ; 2009. p.242-53.
 
3) 小川公明. HLAの基礎知識 3. MHC. 2017 ; 24 : 38-45.
 
4) Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival : comparative analysis of two decades. Transplantation. 2007 ; 84 : 137-43.
 
5) 田邊一成. 移植医療と組織適合性 腎移植における抗HLA抗体の役割. MHC. 2007 ; 14 : 107-16.
 
6) TK Ayna, AO kocyigit. Detection of anti-HLA antibodies by flow cytometer, flow cytometry-select topics, M. Sc. Ingrid Schmid (Ed), InTech. 2016 ; DOI : 10.5772/62553. Available
 
7) 寺岡慧, 甲斐耕太郎. 腎移植における液性拒絶反応. 日腎会誌. 2005 ; 47 : 497-507.
 
8) 田中秀則. 臨床検査における抗ドナー抗体について. 移植. 2016 ; 51 : 429-37.
 
9) 木下明子, 橋本光男, 他. Bead-based assayによる新しい第三世代のリンパ球クロスマッチ法 (ICFA法). 今日の移植, 2011 ; 24 : 278-81.
 
10) 高橋公太. ABO血液型不適合腎移植 なぜ超急性拒絶反応は発生しないのか. Organ Biology. 2011 ; 18 : 11-32.
 
11) KaLn A, Ling M, et al. Desensitization Protocols and their outcome. Clin J Am Soc Nephrol. 2011 ; 6 : 922-36.
 
12) Everly MJ, Rebellat LM, Hasch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013 ; 95 : 410-7.
 
13) 両角國男, 武田朝美. 移植腎病理診断の基礎とBanff分類の変遷. 移植. 2014 ; 49 : 1-5.
 
14) 伊藤壽記. 各臓器移植についての拒絶反応の解説・移植の新しい治療法の紹介 第2回 膵臓移植における免疫学的特異性. MHC. 2009 ; 16 : 229-41.
 
P.73 掲載の参考文献
1) Nelson JL, Koepsell TD, Dugowson CE, et al. Fecundity before disease onset in women with rheumatoid arthritis. Arthritis Rheum. 1993 ; 36 : 7-14.
 
2) Ostensen M. Rheumatoid arthritis : The effect of RA and medication on female fertility. Nat Rev Rheumatol. 2014 ; 10 : 518-9.
 
3) Brouwer J, Hazes JM, Laven JS, et al. Fertility in women with rheumatoid arthritis : influence of disease activity and medication. Ann Rheum Dis. 2015 ; 74 : 1836-41.
PubMed
4) Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012 ; 64 : 2085-94.
 
5) de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight : results of a national prospective study. Arthritis Rheum. 2009 ; 60 : 3196-206.
 
6) Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013 ; 98 : 3785-92.
 
7) Andreoli L, Bertsias GK, Agmon-Levin N,. et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 ; 76 : 476-85.
 
8) Gupta S, Gupta N. Sjogren Syndrome and Pregnancy : A Literature Review. Perm J. 2017 ; 21. 16-47.
 
9) Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit : the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 ; 67 : 313-25.
 
10) Ince-Askan H, Hazes JM, Dolhain RJ. Identifying clinical factors associated with low disease activity and remission of rheumatoid arthritis during pregnancy. Arthritis Care Res (Hoboken). 2017 ; 69 : 1297-303.
 
11) Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy : challenges and solutions. Open Access Rheumatol. 2016 ; 8 : 23-36.
 
12) 日本リウマチ学会, 編, 関節リウマチ診療ガイドライン 2014. 大阪 : メディカルレビュー社 ; 2014. p.47.
 
13) 日本腎臓病学会, 編. 腎疾患患者の妊娠診療 : ガイドライン 2017, 東京 : 診断と治療社 ; 2017. p.20-1.
 
14) de Jesus GR, Mendoza-Pinto C, de Jesus NR, et al. Understanding and managing pregnancy in patients with lupus. Autoimmune Dis. 2015 ; 2015 : 943490.
 
15) 平成27年度日本医療研究開発機構生育疾患克服等総合研究事業「抗リン脂質抗体症候群合併妊娠の治療及び予後に関する研究」研究班. 抗リン脂質抗体症候群合併妊娠の診療ガイドライン. 東京 : 南山堂 ; 2016. p.40-4.
 
16) Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009 ; 103 : 1102-6.
 
P.86 掲載の参考文献
1) Miyata H, Satouh Y, Mashiko D, et al. Sperm calcineurin inhibition prevents mouse fertility with implications for male contraceptive. Science. 2015 ; 350 : 442-5.
PubMed
2) 伊川正人, 監. 受精メカニズム新論争～ドグマの再構築～. 細胞工学. 2014 ; 33 : 361-421.
 
3) Dorin JR, Barratt CL. Importance of beta-defensins in sperm function. Mol Hum Reprod. 2014 ; 20 : 821-6.
 
4) Bianchi E, Doe B, Goulding D, et al. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature. 2014 ; 508 : 483-7.
PubMed
5) Carvacho I, Lee HC, Fissore RA, et al. TRPV3 channels mediate strontium-induced mouse-egg activation. Cell Rep. 2013 ; 5 : 1375-86.
 
P.91 掲載の参考文献
1) Liu Z, Shimada M, Richards JS. The involvement of the Toll-like receptor family in ovulation. J Assist Reprod Gen. 2008 ; 25 : 223-8.
 
2) Hosseini S, Dehghani-Mohammadabadi M, Ghafarri Novin M, et al. Toll-like receptor 4 as a modulator of fertilization and subsequent preimplantation development following in vitro maturation in mice. Am J Reprod Immunol. 2017 Jun 13. doi : 10.1111/aji.12720. [Epub ahead of print].
 
3) Sharara FI, Scott RT Jr, Selfer DB, et al. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol. 1998 ; 179 : 804-12.
 
4) 柴原浩章, 森本真晴, 脇本裕他. 自己免疫性卵巣炎 (早発卵巣不全, 早発閉経). In : 免疫症候群 第2版. 別冊日本臨牀. 東京 : 日本臨牀社 ; 2015. p.223-7.
 
5) Casson PR, Lindsay MS, Pisarska MD, et al. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders : A case series. Hum Reprod. 2000 ; 15 : 2129-32.
 
6) Narkwichean A, Maalouf W, Campbell BK, et al. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve : A meta-analysis. Reprod Biol Endocrinol. 2013 ; 11 : 44.
 
7) Zhang J, Qiu X, Gui Y, et al. Dehydroepiandrosterone improves the ovarian reserve of women with diminished ovarian reserve and is a potential regulator of the immune response in the ovaries. BioScience Trends. 2015 ; 9 : 350-9.
 
8) Gleicher N, Vidali A, Barad DH. Successful treatment of unresponsive thin endometrium. Fertil Steril. 2011 ; 95 : 2123. e13-7.
 
9) Gleicher N, Kim A, Michaeli T, et al. A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies. Hum Reprod. 2013 ; 28 : 172-7,
 
10) Xie Y, Zhang T, Tian Z, et al. Efficacy of intrauterine perfusion of granulocyte colony-stimulating factor (G-CSF) for infertile women with thin endometrium : A systematic review and meta-analysis. Am J Reprod Immunol. 2017 ; e12701.
 
11) Santjohanser C, Knieper C, Franz C, et al. Granulocyte-colony stimulating factor as treatment option in patients with recurrent miscarriage. Arch Immunol Ther Exp. 2013 ; 61 : 159-64.
 
12) Wurfel W. Treatment with granulocyte colony-stimulating factor in patients with repetitive implantation failures and/or recurrent spontaneous abortions. J Reprod Immunol. 2015 ; 108 : 123-35.
 
13) Tanha FD, Shahrokh Tehraninejad E, Ghazi M, et al. The role of G-CSF in recurrent implantation failure : a randomized double blind placebo control trial. Int J Reprod Biomed. 2016 ; 14 : 737-42,
 
14) American Society for Reproductive Medicine. Guideline for providers caring for women and men of reproductive age with possible Zika virus exposure. <http://www.asrm.org/uploadedFiles/ASRM_Content/News_and_Publications/News_and_Research/ASRM/Announcements/2016-01/ASRM_ZikaGuidance.pdf> Updated September 15, 2016.
 
P.99 掲載の参考文献
1) Redline RW, Lu CY. Localization of fetal major histocompatibility complex antigens and maternal leukocytes in murine placenta. Implications for maternalfetal immunological relationship. Lab Invest. 1989 ; 61 : 27-36.
 
2) Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol. 1994 ; 153 : 5516-24.
 
3) King A, Boocock C, Sharkey AM, et al. Evidence for the expression of HLA-C class I mRNA and protein by human first trimester trophoblast. J Immunol. 1996 ; 156 : 2068-76.
 
4) Nagamatsu T, Schust DJ. Review : The immunomodulatory roles of macrophages at the maternal-fetal Interface. Reprod Sci. 2010 ; 17 : 209-18.
 
5) Hanna J, Wald O, Goldman-Wohl D, et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood. 2003 ; 102 : 1569-77.
 
6) Aluvihare VR, Kallikourdi SM, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004 ; 5 : 266-1.
 
7) Koch SD, Liss E, van Lier AW, et al. Alloantigen-induced regulatory CD8+ CD103+ T cells. Hum Immunol. 2008 ; 69 : 737-44.
 
8) Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte Activation. J Exp Med. 2000 ; 192 : 1027-34.
 
9) Petroff MG, Chen L, Phillips TA, et al. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod. 2003. 68 : 1496-504.
 
10) Nagamatsu T, Schust DJ, Sugimoto J, et al. Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. Hum Reprod. 2009 ; 24 : 3160-71.
 
11) Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 ; 202 : 231-7.
 
P.105 掲載の参考文献
1) Tilburgs T, Evans JH, Crespo AC, et al. The HLA-G cycle provides for both NK tolerance and immunity at the maternal-fetal interface. Proc Natl Acad Sci USA. 2015 ; 112 : 13312-7.
 
2) Seshadri S, Sunkara SK. Natural killer cells in female infertility and recurrent miscarriage : a systematic review and meta-analysis. Hum Reprod Update. 2014 ; 20 : 429-38.
PubMed
3) Saito S, Nakashima A, Shima T, et al. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010 ; 63 : 601-10.
PubMed
4) Plaks V, Birnberg T, Berkutzki T, et al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest. 2008 ; 118 : 3954-65.
 
5) Dekel N, Gnainsky Y, Granot I, et al. The Role of Inflammation for a Successful Implantation. Am J Reprod Immunol. 2014 ; 72 : 141-7.
 
6) Ichikawa T, Negishi Y, Shimizu M, et al. alpha-Galactosylceramide-activated murine NK1.1 (+) invariant-NKT cells in the myometrium induce miscarriages in mice. Eur J Immunol. 2016 ; 46 : 1867-77.
 
7) Nadeau-Vallee M, Obari D, Palacios J, et al. Sterile inflammation and pregnancy complications : a review. Reproduction. 2016 ; 152 : R277-92.
 
P.113 掲載の参考文献
1) Hoeven KH, Anyaegbunam A, Hochster H, et al. Clinical significance of increasing histologic severity of acute inflammation in the fetal membranes and umbilical cord. Pediat Pathol Lab Med. 1996 ; 16 : 731-44.
 
2) Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. BJOG. 2003 ; 110 : 124-7.
 
3) Yoneda S, Shiozaki A, Yoneda N, et al. Antibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high sensitive PCR system. Am J Reprod Immunol. 2016 ; 75 : 440-50.
 
4) Romero R, Miranda J, Chaiworapongsa T, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Reprod Immunol. 2014 ; 72 : 458-74.
 
5) Yoneda S, Shiozaki A, Ito M, et al. Accurate prediction for the stage of histological chorioamnionitis before delivery by amniotic fluid IL-8 level. Am J Reprod Immunol. 2015 ; 73 : 568-76.
 
6) Yoneda N, Yoneda S, Niimi H, et al. Polymicrobial amniotic fluid infection with Mycoplasma/Ureaplasma and other bacteria induces severe intra-amniotic inflammation associated with poor perinatal prognosis in preterm labor. Am J Reprod Immunol. 2016 ; 75 : 112-25.
 
7) Cardenas I, Means RE, Aldo P, et al. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol. 2010 ; 185 : 1248-57.
 
8) Maki Y, Furukawa S, Kodama Y, et al. Amniocentesis for threatened preterm labor with intact membranes and the impact on adverse outcome in infants born at 22 to 28 weeks of gestation. Early hum devlop. 2015 ; 91 : 333-7.
 
9) Yoneda S, Shiozaki A, Yoneda N, et al. Prediction of exact delivery time in patients with preterm labor and intact membranes at admission by amniotic fluid interleukin-8 level and preterm labor index. J Obstet Gynecol Res. 2011 ; 37 : 861-6.
 
10) Hatanaka AR, Mattar R, Kawanami TE, et al. Amniotic fluid "sludge" is an independent risk factor for preterm delivery. J Matern Fetal Neonatal Med. 2016 ; 29 : 120-5.
 
11) Romero R, Kusanovic JP, Espinoza J, et al. What is amniotic fluid 'sludge'? Ultrasound Obstet Gynecol. 2007 ; 30 : 793-8.
 
12) Flenady V, Hawley G, Stock OM, et al. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev. 2013 ; CD000246.
 
13) Myhre R, Brantsater AL, Myking S, et al. Intake of probiotic food and risk of spontaneous preterm delivery. Am J Clin Nutr. 2011 ; 93 : 151-7.
 
14) Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011 ; 331 : 337-41.
PubMed
15) Shiozaki A, Yoneda S, Yoneda N, et al. Intestinal microbiota is different in women with preterm birth : Results from terminal restriction fragment length polymorphism analysis. PLoS One. 2014 ; 9 : e111374.
 
16) Jarde A, Lutsiv O, Park CK, et al. Effectiveness of progesterone, cerclage and pessary for preventing preterm birth in singleton pregnancies : a systematic review and network meta-analysis. BJOG. doi : 10.1111/1471-0528.14513.
 
P.122 掲載の参考文献
1) Browsen IA, Robertson WB,Dixon HG. The role of the spiral arteries in pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972 ; 1 : 177-91
 
2) Reister F, Frank HG, Heyl W, et al. The distribution of macrophages in spiral arteries of the placental bed in pre-eclampsia differs from that in healthy patients. Placenta. 1993 ; 20 : 229-33.
 
3) Le Bouteiller P, Pizzato N, Barakonyi A, et al. HLA-G, pre-eclampsia, immunity and vascular events. J Reprod Immunol. 2003 ; 59 : 219-34.
 
4) Stallmach T, Hebisch G, Orban P, et al. Aberrant positioning of trophoblast and lymphocytes in the feto-maternal interface with pre-eclampsia. Virchows Arch. 1999 ; 434 : 207-11.
 
5) Harsem NK, Roald B, Braekke K, et al. Acute atherosis in decidual tissue : not associated with systemic oxidative stress in preeclampsia. Placenta. 2007 ; 28 : 958-64.
 
6) Shiozaki A, Matsuda Y, Satoh S, et al. Impact of fetal sex in pregnancy-induced hypertension and preeclampsia in Japan. J Reprod Immunol. 2011 ; 89 : 133-9.
 
7) Goldman-Wohl DS, Ariel I, Greenfield C, et al. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. Mol Hum Reprod. 2000 ; 6 : 88-95.
 
8) Yie SM, Li LH, Li YM, et al. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. Am J Obstet Gynecol. 2004 ; 191 : 525-9.
 
9) Saito S, Sakai M, Sasaki Y, et al. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1 : Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol. 1999 ; 117 : 550-5.
 
10) Toldi G, Saito S, Shima T, et al. The frequency of peripheral blood CD4+ CD25high FoxP3+ and CD4+ CD25- FoxP3+ regulatory T cells in normal pregnancy and pre-eclampsia. Am J Reprod Immunol. 2012 ; 68 : 175-80.
 
11) Croy BA, Ashkar AA, Minhas K, et al. Can murine uterine natural killer cells give insights into the pathogenesis of preeclampsia? J Soc Gynecol Investig. 2000 ; 7 : 12-20.
 
12) Saftlas AF, Beydoun H, Triche E. Immunogenetic determinants of preeclampsia and related pregnancy disorders : a systematic review. Obstet Gynecol. 2005 ; 106 : 162-72.
PubMed
13) Triche EW, Harland KK, Field EH, et al. Maternal-fetal HLA sharing and preeclampsia : variation in effects by seminal fluid exposure in a case-control study of nulliparous women in Iowa. J Reprod Immunol. 2014 ; 101-2 : 111-9.
 
14) Hiby SE, Walker JJ, O'shaughnessy KM, Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004 ; 200 : 957-65.
 
15) Redman CWG, Sargent IL. Latest advances in understanding preeclampsia Science. 2005 ; 308 : 1592-4.
 
16) 山本樹生, 千島史尚, 東裕福, 他. 抗リン脂質抗体と妊娠. Reproductive Immunology and Biology. 2013 ; 28 : 11-7.
 
17) Walther T, Wallukat G, Jank A, et al. Aigiotensin II type 1 recptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005 ; 46 : 1275-9.
 
P.129 掲載の参考文献
1) Yuan M, Jordan F, McInnes IB, et al. Leukocytes are primed in peripheral blood for activation during term and preterm labour. Mol Hum reprod. 2009 ; 15 : 713-24.
 
2) Sakamoto Y, Moran P, Bulmer JN, et al. Macrophages and not granulocytes are involved in cervical ripening. J Reprod Immunol. 2005 ; 66 : 161-73.
 
3) Gomez-Lopez N, StLouis D, Lehr MA, et al. Immune cells in term and preterm labor. Cell Mol Immunol. 2014 ; 11 : 571-81.
 
4) Dubicke A, Fransson E, Centini G, et al. Pro-inflammatory and anti-inflammatory cytokines in human preterm and term cervical ripening. J Reprod Immunol. 2010 ; 84 : 176-85.
 
5) Samejima T, Nagamatsu T, Schust DJ, et al. Labor prediction based on the expression patterns of multiple genes related to cervical maturation in human term pregnancy. Am J Reprod Immunol. 2017 ; 78 : 5.
 
6) Samejima T, Nagamatsu T, Schust DJ, et al. Elevated concentration of secretory leukocyte protease inhibitor in the cervical mucus before delivery. Am J Obstet Gynecol. 2016 ; 214 : 741. e1-7.
 
P.136 掲載の参考文献
1) 矢田純一. 医系免疫学. 改訂14版. 東京 : 中外医学社 ; 2016. p.27-37, 896-903.
 
2) Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012 ; 2012 : 985646.
 
3) Ellinger I, Fuchs R. hFcRn-mediated transplacental immunoglobulin G transport : protection of and threat to the human fetus and newborn. Wien Med Wochenschr. 2012 ; 162 : 207-13.
 
4) Hoftman AC, Hernandez MI, Lee KW, et al. Newborn illnesses caused by transplacental antibodies. Adv Pediatr. 2008 ; 55 : 271-304.
 
5) 宮川義隆, 柏木浩和, 高蓋寿朗, 他. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液. 2014. 55 : 934-47.
 
6) 今村孝, 大戸斉. 同種免疫性新生児血小板減少症. 日本臨牀. 別冊免疫症候群 I : 2015. p.919-23.
 
7) Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis. 2013 ; 26 : 248-53.
 
P.144 掲載の参考文献
1) Takamura M, Koga K, Izumi G, et al. Neutrophil depletion reduces endometriotic lesion formation in mice. Am J Reprod Immunol. 2016 ; 76 : 193-8.
 
2) Takamura M, Osuga Y, Izumi G, et al. Interleukin-17A is present in neutrophils in endometrioma and stimulates the secretion of growth-regulated oncogene-alpha (Gro-alpha) from endometrioma stromal cells. Fertil Steril. 2012 ; 98 : 1218-24.e1-2.
 
3) Izumi G, Koga K, Takamura M, et al. Mannose receptor is highly expressed by peritoneal dendritic cells in endometriosis. Fertil Steril. 2017 ; 107 : 167-73e2.
 
4) Hirata T, Osuga Y, Hamasaki K, et al. Interleukin (IL) -17A stimulates IL-8 secretion, cyclooxygensase-2 expression, and cell proliferation of endometriotic stromal cells. Endocrinology. 2008 ; 149 : 1260-7.
 
5) Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol. 2006 ; 72 : 85-93.
 
6) Miyashita M, Koga K, Izumi G, et al. Effects of 1,25-dihydroxy vitamin D3 on endometriosis. J Clin Endocrinol Metab. 2016 ; 101 : 2371-9.
 
7) Taguchi A, Koga K, Kawana K, et al. Resveratrol enhances apoptosis in endometriotic stromal cells. Am J Reprod Immunol. 2016 ; 75 : 486-92.
 

II 各論

P.149 掲載の参考文献
1) Specken J. Een merkwaardig geval van allerie in de gynacol. Ned Tjidschr Verloskd Gynaecol. 1958 ; 58 : 314-8.
 
2) Ebo DG, Steven WJ, Bridts CH, et al. Human seminal plasma anaphylaxis (HSPA) : case report and literature review. Allergy. 1995 ; 50 : 747-50.
 
3) Presti ME, Druce HM. Hypersensitivity reactions to human seminal plasma. Ann Allergy. 1989 ; 63 : 477-81.
 
4) Woo-Jung S, Deok-In K, Min-Hey K, et al. Human seminal plasma allergy : successful pregnancy after prophylactic anti-histamine treatment. Asia Pac Allergy. 2011 ; 1 : 168-71.
 
5) Gabriele CN, Peter von den D. Human seminal plasma allergy-a rare cause of recurrent anaphylaxis. JDDG. 2007 ; 5 : 34-6.
 
6) Jessica T, Jonathan AB. Fertility and human seminal plasma (HSP) hypersensitivity. Ann Allergy Asthma Immunol. 2013 ; 111 : 145.
 
7) Banu B, Joan M, Wai Y. Human seminal plasma hypersensitivity : an unusual indication for in vitro fertilization. Euro J Obstet Gynecol Reprod Biol. 2010 ; 153 : 226-7.
 
8) Cynthia F, Isabelle B, Vanina de L, et al. Successful pregnancy by insemination of spermatozoa in a woman with a human seminal plasma allergy : should in vitro fertilization be considered first? Fertil Steril. 2010 ; 94 : 2 : 753.e1-3.
 
P.154 掲載の参考文献
1) Shimasaki S, Moore RK, Otsuka F, et al. The bone morphogenetic protein system in mammalian reproduction. Endocr Rev. 2004. 25 : 72-101.
 
2) Fraser HM, Wilson H, Rudge JS, et al. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. J Clin Endocrinol Metab. 2005 ; 90 : 1114-22.
 
3) 吉野修, 大須賀穣. 卵胞発育と血管新生. ホルモンフロンティア. 2010 ; 17 : 227-35.
 
4) Turner EC, Hughes J, Wilson H, et al. Conditional ablation of macrophages disrupts ovarian vasculature. Reproduction. 2011 ; 141 : 821-31.
 
5) Van der Hoek KH, Maddocks S, Woodhouse CM, et al. Intrabursal injection of clodronate liposomes causes macrophage depletion and inhibits ovulation in the mouse ovary. Biol Reprod. 2000 ; 62 : 1059-66.
 
6) Cohen PE, Zhu L, Pollard JW. Absence of colony stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice disrupts estrous cycles and ovulation. Biol Reprod. 1997 ; 56 : 110-8.
 
7) Chang RJ, Gougeon A, Erickson GF, Evidence for a neutrophil-interleukin-8 system in human folliculogenesis. Am J Obstet Gynecol. 1998 ; 178 : 650-7.
 
8) Makinoda S, Hirosaki N, Waseda T, et al. Granulocyte colony-stimulating factor (G-CSF) in the mechanism of human ovulation and its clinical usefulness. Curr Med Chem. 2008 ; 15 : 604-13.
 
9) Hellberg P, Thomsen P, Janson PO, et al. Leukocyte supplementation increases the luteinizing hormone-induced ovulation rate in the in vitro-perfused rat ovary. Biol Reprod. 1991 ; 44 : 791-7.
 
10) Brannstrom M, Bonello N, Norman RJ, et al. Reduction of ovulation rate in the rat by administration of a neutrophil-depleting monoclonal antibody. J Reprod Immunol. 1995 ; 29 : 265-70.
 
11) Akiyama I, Yoshino O, Osuga Y, et al. The role of bone morphogenetic protein 6 in accumulation and regulation of neutrophils in the human ovary. Reprod Sci. 2014 ; 21 : 772-7.
 
12) Shibata T, Makinoda S, Waseda T, et al. Granulocyte colony-stimulating factor as a potential inducer of ovulation in infertile women with luteinized unruptured follicle syndrome. Transl Res. 2016 ; 171 : 63-70.
 
13) Richards JS. Ovulation : new factors that prepare the oocyte for fertilization. Mol Cell Endocrinol. 2005 ; 234 : 75-9.
 
14) Cohen-Fredarow A, Tadmor A, Raz T, et al. Ovarian dendritic cells act as a double-edged pro-ovulatory and anti-inflammatory sword. Mol Endocrinol. 2014 ; 28 : 1039-54.
 
P.161 掲載の参考文献
1) 森崇英. 第10回 排卵 (I) : 卵胞破裂-LH励起性の卵胞壁生理的炎症論HORMONE FRONTIER IN GYNECOLOGY. 2011 ; 18 : 342-9.
 
2) Orio F, Palomba S, Cascella T, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endcrinol Metab. 2005 ; 2 : 2-5.
 
3) Esfahanian F, Zamani MM, Heshmat R, et al. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overwight women polycystic ovary syndrome. J Obstet Gynecol Res. 2013 ; 39 : 806-13.
 
4) Chen Y, Li M, Deng H, et al. Impact of metformin on C-reactive protein levels in women with women with polycystic ovary syndrome : meta-analysis. Oncotarget. 2017 ; 8 : 35425-34.
 
5) Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 ; 112 : 1976-808.
 
6) Peng Z, Sun Y, Lv X, et al. Interleukin-6 levels in women with polycystic ovary syndrome : a systematic review and meta-analysis. PLOS ONE. 2016 ; 11 : e0148531.
 
7) Victor VM, Rovira-Llopis S, Bariuls C, et al. Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance. Eur J Endocrinol. 2015 ; 173 : 683-91.
 
8) Adams J, Liu Z, Athena Y, et al. Enhanced inflammatory transcriptome in the granulosa cells of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2016 ; 101 : 3459-68.
 
9) Panidis D, Kourtis A, Farmakiotis D, et al. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 2003 ; 18 : 1790-6.
 
10) Majuri A, Santaniemi M, Rautio K, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS : a randomized placebo-controlled study. Eur J Endocrinol. 2007 ; 156 : 263-9.
 
11) Al-Eisa E, Gabr SA, Alghadir AH. Effects of supervised aerobic training on the levels of anti-Mullerian hormone and adiposity measures in women with normo-ovulatory and polycystic ovary syndrome. J Pak Med Assoc. 2017 ; 67 : 499-507.
 
12) Singh A, Bora P, Krishna A. Direct action of adiponectin ameliorates increased androgen synthesis and reduces insulin receptor expression in the polycystic ovary. Biochem Biophys Res Commun. 2017 ; 488 : 509-15.
 
13) Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica. 2016 ; 2016 : 4071735.
 
14) Angstwurm MWA, Gartner R, Ziegler-Heitbrock. Cyclic plasma IL-6 levels during normal menstrual cycle. Cytokine. 1997 ; 9 : 370-4.
 
15) Samsami DA, Razmjoei P, Parsanezhad ME. Serum levels of anti-histone and anti-double-strand DNA antibodies polycystic before and after laparoscopic ovarian drilling in women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India. 2014 ; 64 : 47-52.
 
16) Escobar-Morreale HF, Roldan B, Barrio R, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women type I diabetes mellitus. J Clin Endocrinol Metab. 2000 ; 85 : 4182-7.
 
P.167 掲載の参考文献
1) Ebrahimi M, AsbaghIran FA. The role of autoimmunity in premature ovarian failure. J Reprod Med. 2015 ; 13 : 461-72.
 
2) Komorowska B. Autoimmune premature ovarian failure. Menopause Rev. 2016 ; 15 : 210-14.
 
3) Li J, Kawamura K, Cheng Y, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci USA. 2010 ; 107 : 10280-4.
PubMed
4) Kawamura K, Cheng Y, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA. 2013 ; 110 : 17474-9.
PubMed
5) Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles : a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016 ; 28 : 217-22.
 
P.173 掲載の参考文献
1) Shibahara H, Shiraishi Y, Hirano Y, et al. Relationship between level of serum sperm immobilizing antibody and its inhibitory effect on sperm migration through cervical mucus in immunologically infertile women. Am J Reprod Immunol. 2007 ; 57 : 142-6.
PubMed
2) Taneichi A, Shibahara H, Hirano Y, et al. Sperm immobilizing antibodies in the sera of infertile women cause low fertilization rates and poor embryo quality in vitro. Am J Reprod Immunol. 2002 ; 47 : 46-51.
PubMed
3) Naz RK, Menge AC.Antisperm antibodies : origin, regulation, and sperm reactivity in human infertility. Fertil Steril. 1994 ; 61 : 1001-13.
 
4) Koyama K, Kubota K, Ikuma K, et al. Application of the quantitative sperm immobilization test for follow-up study of sperm-immobilizing antibody in the sera of sterile women. Int J Fertil. 1988 ; 33 : 201-6.
PubMed
5) Kobayashi S, Bessho T, Shigeta M, et al. Correlation between quantitative antibody titers of sperm immobilizing antibodies and pregnancy rates by treatments. Fertil Steril. 1990 ; 54 : 1107-13.
PubMed
6) Isojima S, Li TS, Ashitaka Y, et al. Immunologic analysis of sperm-immobilizing factor found in sera of women with unexplained sterility. Am J Obstet Gynecol. 1968 ; 101 : 677-83.
 
7) Isojima S, Koyama k. Quantitative estimation of sperm immobilizing antibody in the sera of women with sterility of unknown etiology : the 50 % sperm immobilization unit (SI50). Excerpta Med Int Congr Ser. 1976 ; 370 : 10-5.
 
8) Wakimoto Y, Fukui A, Kojima T, et al. Application of Computer-Aided Sperm Analysis (CASA) for Detecting Sperm Immobilizing Antibody. Am J Reprod Immunol (submitted).
 
P.178 掲載の参考文献
1) Mannikko M, Tormala RM, Tuuri T, et al. Association between sequence variations in genes encoding human zona pellucida glycoproteins and fertilization failure in IVF. Hum Reprod. 2005 ; 20 : 1578-85.
 
2) Shivers CA, Dunbar BS. Autoantibodies to zona pellucida : a possible cause for infertility in women. Science. 1977 ; 197 : 1082-4.
PubMed
3) Kamada T, Maegawa M, Daitoh T, et al. Sperm-zona interavtion and immunological infertility. Reprod Med Bilo. 2006 ; 5 95-104.
 
4) Koyama K, Hasegawa A, Mochida N. Follicular dysfunction induced by autoimmunity to zona pellucida. Reprod Bilo. 2005 ; 5 : 269-78.
 
5) Kim JH, Jee BC. Empty follicle syndrome. Clin Exp Reprod Med. 2012 ; 39 : 132-7.
 
6) Stanger JD, Stevenson K, Lakmaker A, et al. Pregnancy following fertilization of zona-free, coronal cell intact human ova : Case Report. Case Report. 2001 ; 16 : 164-7.
 
P.184 掲載の参考文献
1) 城田京子, 日高直美, 詠田由美, 他. 抗セントロメア抗体と多前核胚 その意義と治療 (解説). 日本卵子学会誌. 2016 ; 1 : 35-40.
 
2) Shirota K, Nagata Y, Honjou K, et al. Involvement of anticentromere antibody in interference with oocyte meiosis and embryo cleavage. Fertil Steril. 2011 ; 95 : 2729-31.
 
3) 日高直美, 城田京子, 詠田由美, 他. 抗セントロメア抗体が卵および胚に及ぼす影響. 福岡大学医学紀要. 2015 ; 42 : 81-6.
 
4) 北坂浩也, 福永憲隆, 吉村友邦, 他. 多前核形成が高頻度に認められた1症例の多前核胚解析. 日本受精着床学会雑誌. 2015 ; 32 : 219-22.
 
5) 楠田朋代, 吉川優子, 原田義久, 他. 抗核抗体Discrete speckled型が強陽性であり, 多前核胚を高頻度に認めた症例に対する薬物療法および紡錘体観察の試み. 医療法人絹谷産婦人科クリニック. 日本受精着床学会雑誌. 2015 ; 32 : 239-45.
 
P.189 掲載の参考文献
1) Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy : the 'black box' of early pregnancy loss. Hum Reprod Update. 2002 ; 8 : 333-43.
PubMed
2) Makrigiannakis A, Petsas G, Toth B, et al. Recent advances in understanding immunology of reproductive failure. J Reprod Immunol. 2011 ; 90 : 96-104.
 
3) Hunt JS, Andrews GK, Wood GW. Normal trophoblasts resist induction of class I HLA. J Immunol. 1987 ; 138 : 2481-7.
 
4) King A, Burrows TD, Hiby SE, et al. Surface expression of HLA-C antigen by human extravillous trophoblast. Placenta. 2000 ; 21 : 376-87.
 
5) Hunt JS, Petroff MG, McIntire RH, et al. HLA-G and immune tolerance in pregnancy. FASEB J. 2005 ; 19 : 681-93.
 
6) Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004 ; 5 : 266-71.
 
7) Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA. 1995 ; 273 : 1933-6.
 
8) Raghupathy R, Makhseed M, Azizieh F, et al. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod. 2000 ; 15 : 713-8.
 
9) Ng SC, Gilman-Sachs A, Thaker P, et al. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am J Reprod Immunol. 2002 ; 48 : 77-86.
 
10) Kwak-Kim JY, Chung-Bang HS, Ng SC, et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod. 2003 ; 18 : 767-73.
 
11) Ledee-Bataille N, Bonnet-Chea K, Hosny G, et al. Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with a history of repeated in vitro fertilization-embryo transfer failure. Fertil Steril. 2005 ; 83 : 598-605.
 
12) Inagaki N, Stern C, McBain J, et al. Analysis of intra-uterine cytokine concentration and matrix-metalloproteinase activity in women with recurrent failed embryo transfer. Hum Reprod. 2003 ; 18 : 608-15.
 
13) Boomsma CM, Kavelaars A, Eijkemans MJ, et al. Endometrial secretion analysis identifies a cytokine profile predictive of pregnancy in IVF. Hum Reprod. 2009 ; 24 : 1427-35.
 
14) Moffett A, Shreeve N. First do no harm : uterine natural killer (NK) cells in assisted reproduction. Hum Reprod. 2015 ; 30 : 1519-25.
 
15) Saito S, Nishikawa K, Morii T, et al. Cytokine production by CD16-CD56bright natural killer cells in the human early pregnancy decidua. Int Immunol. 1993 ; 5 : 559-63.
PubMed
16) Verma S, King A, Loke YW. Expression of killer cell inhibitory receptors on human uterine natural killer cells. Eur J Immunol. 1997 ; 27 : 979-83.
 
17) Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006 ; 12 : 1065-74.
PubMed
P.194 掲載の参考文献
1) Hiraoka T, Saito-Fujita T, Hirota Y. How does Progesterone support embryo implantation? J Mammalian Ova Res. 2015 ; 32 : 87-94.
 
2) 江頭真宏, 廣田泰. 種差からみた着床-ヒトとの共通点と相違点-. HORMONE FRONTIER IN GYNECOLOGY. 2015 ; 22 : 11-7.
 
3) Cha J, Sun X, Dey SK. Mechanisms of implantation : strategies for successful pregnancy. Nat Med. 2012 ; 18 : 1754-67.
PubMed
4) Daikoku T, Ogawa Y, Terakawa J, et al. Lactoferrin-iCre : a new mouse line to study uterine epithelial gene function. Endocrinology. 2014 ; 155 : 2718-24.
 
5) Daikoku T, Cha J, Sun X, et al. Conditional deletion of Msx homeobox genes in the uterus inhibits blastocyst implantation by altering uterine receptivity. Dev Cell. 2011 ; 21 : 1014-25.
PubMed
6) Rodesch F, Simon P, Donner C, et al. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992 ; 80 : 283-5.
 
7) Gassmann M, Fandrey J, Bichet S, et al. Oxygen supply and oxygen-dependent gene expression in differentiating embryonic stem cells. Proc Natl Acad Sci USA. 1996 ; 93 : 2867-72.
 
8) Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995 ; 270 : 1230-7.
 
9) Daikoku T, Matsumoto H, Gupta RA, et al. Expression of hypoxia-inducible factors in the peri-implantation mouse uterus is regulated in a cell-specific and ovarian steroid hormone-dependent manner. Evidence for differential function of HIFs during early pregnancy. J Biol Chem. 2003 ; 278 : 7683-91.
 
P.200 掲載の参考文献
1) Ruiz-Alonso M, Blesa D, Diaz-Gimeno P, et al. The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. Fertil Steril. 2013 ; 100 : 818-24.
PubMed
2) Harton GL, Munne S, Surrey M, et al. Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. Fertil Steril. 2013 ; 100 : 1695-703.
PubMed
3) Fox C, Morin S, Jeong JW, et al. Local and systemic factors and implantation : what is the evidence? Fertil Steril. 2016 ; 105 : 873-84.
 
4) Ruiz-Alonso M, Blesa D, Diaz-Gimeno P, et al. The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. Fertil Steril. 2013 ; 100 : 818-24.
PubMed
5) Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JA, et al. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature. Fertil Steril. 2011 ; 95 : 50-60.
 
6) Ruiz-Alonso M, Galindo N, Pellicer A, et al. What a difference two days make : "personalized" embryo transfer (pET) paradigm : A case report and pilot study. Hum Reprod. 2014 ; 29 : 1244-7.
 
7) Comstock IA, Diaz-Gimeno P, Cabanillas S, et al. Does an increased body mass index affect endometrial gene expression patterns in infertile patients? A functional genomics analysis. Fertil Steril. 2017 ; 107 : 740-8.
 
P.204 掲載の参考文献
1) Kariya M, Kanzaki H, Takakura K, et al. Interleukin-1 inhibits in vitro decidualization of human endometrial stromal cells. J Clin Endocrinol Metab. 1991 ; 73 : 1170-4.
PubMed
2) Takabatake K, Fujiwara H, Goto Y, et al. Intravenous administration of splenocytes in early pregnancy changes the implantation window in mice. Hum Reprod. 1997 ; 12 : 583-5.
PubMed
3) Takabatake K, Fujiwara H, Goto Y, et al. Splenocytes in early pregnancy promote embryo implantation by regulating endometrial differentiation in mice. Hum Reprod. 1997 ; 12 : 2102-7.
PubMed
4) Fujita K, Nakayama T, Takabatake K, et al. Administration of thymocytes derived from non-pregnant mice induces an endometrial receptive stage and leukaemia inhibitory factor expression in the uterus. Hum Reprod. 1998 ; 13 : 2888-94.
PubMed
5) Egawa H1, Fujiwara H, Hirano T, et al. Peripheral blood mononuclear cells in early pregnancy promote invasion of human choriocarcinoma cell line, BeWo cells. Hum Reprod. 2002 ; 17 : 473-80.
 
6) Nakayama T, Fujiwara H, Maeda M, et al. Human peripheral blood mononuclear cells (PBMC) in early pregnancy promote embryo invasion in vitro : HCG enhances the effects of PBMC. Hum Reprod. 2002 ; 17 : 207-12.
PubMed
7) Kosaka K, Fujiwara H, Tatsumi K, et al. Human peripheral blood mononuclear cells enhance cell-cell interaction between human endometrial epithelial cells and BeWo-cell spheroids. Hum Reprod. 2003 ; 18 : 19-25.
 
8) Kosaka K, Fujiwara H, Tatsumi K, et al. Human chorionic gonadotropin (HCG) activates monocytes to produce interleukin-8 via a different pathway from luteinizing hormone/HCG receptor system. J Clin Endocrinol Metab. 2002 ; 87 : 5199-208.
 
9) Fazleabas AT, Donnelly KM, Srinivasan S, et al. Modulation of the baboon (Papio anubis) uterine endometrium by chorionic gonadotrophin during the period of uterine receptivity. Proc Natl Acad Sci USA. 1999 ; 96 : 2543-8.
 
10) Kane N, Kelly R, Saunders PT, et al. Proliferation of uterine natural killer cells is induced by human chorionic gonadotropin and mediated via the mannose receptor. Endocrinology. 2009 ; 150 : 2882-8.
PubMed
11) Schumacher A, Brachwitz N, Sohr S, et al. Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. J Immunol. 2009 ; 182 : 5488-97.
PubMed
12) Schumacher A, Heinze K, Witte J, et al. Human chorionic gonadotropin as a central regulator of pregnancy immune tolerance. J Immunol. 2013 ; 15 ; 190 : 2650-8.
 
13) Fujiwara H. Do circulating blood cells contribute to maternal tissue remodeling and embryo-maternal cross-talk around the implantation period? Mol Hum Reprod. 2009 ; 15 : 335-43.
PubMed
14) Yoshioka S, Fujiwara H, Nakayama T, et al. Intrauterine administration of autologous peripheral blood mononuclear cells promotes implantation rates in patients with repeated failure of IVF-embryo transfer. Hum Reprod. 2006 ; 21 : 3290-4.
PubMed
15) Okitsu O, Kiyokawa M, Oda T, et al. Intrauterine administration of autologous peripheral blood mononuclear cells increases clinical pregnancy rates in frozen/thawed embryo transfer cycles of patients with repeated implantation failure. J Reprod Immunol. 2011 ; 92 : 82-7.
PubMed
16) Makrigiannakis A, BenKhalifa M, Vrekoussis T, et al. Repeated implantation failure : a new potential treatment option. Eur J Clin Invest. 2015 ; 45 : 380-4.
PubMed
17) Madkour A, Bouamoud N, Louanjli N, et al. Intrauterine insemination of cultured peripheral blood mononuclear cells prior to embryo transfer improves clinical outcome for patients with repeated implantation failures. Zygote. 2015 ; 23 : 1-12.
 
P.209 掲載の参考文献
1) Sasaki Y, Sakai M, Saito S, et al. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Moi Hum Reprod.2004 ; 10 : 347-53.
 
2) Shiotani M, Mori T, Noda Y. Embryo-dependent induction of uterine receptivity assessed by an in vitro model of implantation in mice. Biol Reprod. 1993 ; 49 : 794-801.
 
3) Goto S, Shiotani M, Noda Y, et al. Effectiveness of two-step (consecutive) embryo transfer in patients who have two embryos on day 2 : comparison with cleavage-stage embryo transfer. Fertil Steril. 2005 ; 83 : 721-3.
 
4) Goto S, Kokeguchi S, Shiotani M, et al. Stimulation of endometrium embryo transfer (SEET) : injection of embryo culture supernatant into the uterine cavity before blastocyst transfer can improve implantation and pregnancy rates. Fertil Steril. 2007 ; 88 : 1339-43.
 
5) Goto S, Kokeguchi S, Shiotani M, et al. Stimulation of endometrium embryo transfer can improve implantation and pregnancy rates for patients undergoing assisted reproductive technology for the first time with a high-grade blastocyst. Fertil Steril. 2009 ; 92 : 1264-8.
 
P.213 掲載の参考文献
1) 藤井俊策, 湯澤映, 田中加奈子, 他. 生殖における精漿の免疫修飾作用 : review. 青森臨産婦誌. 2006 ; 21 ; 16-31.
 
2) Kawano N, Araki N, Yoshida K, et al. Seminal vesicle protein SVS2 is required for sperm survival in the uterus. Proc Natl Acad Sci U S A. 2014 ; 111 : 4145-50.
PubMed
3) Schjenken JE, Robertson SA. Seminal fluid signalling in the female Reproductive Tract : Implications for reproductive success and offspring health. Adv Exp Med Biol. 2015 ; 868 : 127-58.
 
4) Shima T, Inada K, Nakashima A, et al. Paternal antigen-specific proliferating regulatory T cells are increased in uterine-draining lymph nodes just before implantation and in pregnant uterus just after implantation by seminal plasma-priming in allogeneic mouse pregnancy. J Reprod Immunol. 2015 ; 108 : 72-82.
 
5) Tremellen KP, Valbuena D, Landeras J, et al. The effect of intercourse on pregnancy rates during assisted human reproduction. Hum Reprod. 2000 ; 15 : 2653-8.
 
6) Bromfield JJ, Schjenken JE, Chin PY, et al. Maternal tract factors contribute to paternal seminal fluid impact on metabolic phenotype in offspring. Proc Natl Acad Sci U S A. 2014 ; 111 : 2200-5.
 
P.219 掲載の参考文献
1) Brinster RL, Zimmermann J. Spermatogenesis following male germ cell transplantation. Proc Natl Acad Sci USA. 1994 ; 91 : 11298-302.
 
2) Sofikitis N, Kaponis A, Mio Y, et al. Germ cell transplantation : a review and progress report on ICSI from spermatozoa generated in xenogeneic testes. Hum Reprod Update. 2003 ; 3 : 291-307.
 
3) Itoh M. Testicular Autoimmunity. A cause of male infertility. Tokyo : Springer ; 2017. p.1-232.
 
4) Qu N, Naito M, Li J, et al. Xenogeneic and endogenous spermatogenesis following transplantation of rat germ cells into testes of immunocompetent mice. Reprod Fertil Dev. 2012 ; 24 : 337-43.
 
5) Hirayanagi Y, Qu N, Hirai S, et al. Busulfan pretreatment for transplantation of rat spermatogonia differentially affects immune and reproductive systems in male recipient mice. Anat Sci Int. 2015 ; 90 : 264-74.
 
P.224 掲載の参考文献
1) Ito C, Toshimori K. Acrosome markers of human sperm. Anat Sci Int. 2016 ; 91 : 128-42.
 
2) Kwon WS, Rahman MS, Lee JS, et al. Discovery of predictive biomarkers for litter size in boar spermatozoa. Mol Cell Proteomics. 2015 ; 14 : 1230-40.
 
3) Ito C, Akutsu H, Yao R, et al. Oocyte activation ability correlates with head flatness and presence of perinuclear theca substance in human and mouse sperm. Hum Reprod. 2009 ; 24 : 2588-95.
PubMed
4) Saxena DK, Oh-Oka T, Kadomatsu K, et al. Behaviour of a sperm surface transmembrane glycoprotein basigin during epididymal maturation and its role in fertilization in mice. Reproduction. 2002 ; 123 : 435-44.
 
5) Tollner TL, Bevins CL, Cherr GN. Multifunctional glycoprotein DEFB126-a curious story of defensin-clad spermatozoa. Nat Rev Urol. 2012 ; 9 : 365-75.
 
6) Toshimori K, Araki S, Tanii I, et al. Masking the cryptodeterminant on the 54-kilodalton mouse sperm surface antigen. Biol Reprod. 1992 ; 47 : 1161-7.
 
7) Stites DP, Erickson RP. Suppressive effect of seminal plasma on lymphocyte activation. Nature. 1975 ; 253 : 727-9.
 
8) Nocera M, Chu TM. Transforming growth factor β as an immunosuppressive protein in human seminal plasma. Am J Reprod Immunol. 1993 ; 30 : 1-8.
 
P.229 掲載の参考文献
1) 畠山茂. 人睾丸萎縮の病理. 日本病理学会誌. 1984 ; 73 : 3-29.
 
2) 平井宗一, 伊藤正裕. 精巣病理学者畠山茂の残した日本人剖検所見が示唆するもの. Reproductive Immunology and Biology (日本生殖免疫学会誌). 2012 ; 27 : 7-13.
 
3) Itoh M. Testicular Autoimmunity. A cause of male infertility. Tokyo : Springer ; 2017. p.1-232.
 
4) 伊藤正裕. 精巣と免疫. 産婦人科の実際. 2000 ; 49 : 309-19.
 
5) 伊藤正裕. 生殖腺とリンパ性機関の発生学的連関. Reproductive Immunology and Biology (日本生殖免疫学会誌). 2009 ; 24 : 63-9.
 
P.232 掲載の参考文献
1) Eid NA, Shibata MA, Ito Y, et al. Involvement of Fas system and active caspases in apoptotic signalling in testicular germ cells of ethanol-treated rats. Int J Androl. 2002 ; 25 : 159-67.
 
2) Eid N, Ito Y, Otsuki Y. Enhanced mitophagy in Sertoli cells of ethanol-treated rats : Morphological evidence and clinical relevance. J Mol Histol. 2012 ; 43 : 71-80.
 
3) Eid N, Ito Y, Horibe A, et al. Ethanol-induced mitophagy in liver is associated with activation of the PINK1-Parkin pathway triggered by oxidative DNA damage. Histol Histopathol 2016 ; 31 : 1143-59.
 
4) Horibe A, Eid N, Ito Y, et al. Upregulated autophagy in Sertoli cells of ethanol-treated rats Is associated with induction of inducible nitric oxide synthase (iNOS), androgen receptor suppression and germ cell apoptosis. Int J Mol Sci. 2017 ; 18 : 1061 ; doi : 10.3390/ijms18051061.
 
5) Otsuki Y. Tissue specificity of apoptotic signal transduction. Med Electron Microsc. 2004 ; 37 : 163-9.
 
P.238 掲載の参考文献
1) 坂部貢. 環境化学物質と化学物質過敏症. アレルギーの臨床. 2016 ; 36 : 16.
 
2) Itoh M, Terayama H, Naito M, et al. Tissue microcircumstances for leukocytic infiltration into the testis and epididymis in mice. J Reprod Immunol. 2005 ; 67 : 57-67.
 
3) Hirai S, Naito M, Terayama H, et al. The origin of lymphatic capillaries in murine testes. J Androl. 2012 ; 33 : 745-51.
 
4) Terayama H, Yoshimoto T, Hirai S, et al. Contribution of IL-12/IL-35 Common Subunit p35 to Maintaining the Testicular Immune Privilege. PLoS One. 2014 ; 9 : e96120.
 
5) Ablake M, Itoh M, Terayama H, et al. Di- (2-ethylhexyl) phthalate induces severe aspermatogenesis in mice, however, subsequent antioxidant vitamins supplementation accelerates regeneration of the seminiferous epithelium. Int J Androl. 2004 ; 27 : 274-81.
 
6) Ogawa Y, Itoh M, Hirai S, et al. Cadmium exposure increases susceptibility to testicular autoimmunity in mice. J Appl Toxicol. 2013 ; 33 : 652-60.
 
7) Kitaoka M, Hirai S, Terayama H, et al. Effects on the local immunity in the testis by exposure to di- (2-ethylhexyl) phthalate (DEHP) in mice. J Reprod Dev. 2013 ; 59 : 485-90.
 
8) Ogawa Y, Qu N, Kitaoka M, et al. The changes of the immune circumstance in the testicular tissues of mice treated with low dose of cadmium. Reproductive Immunology and Biology. 2007 ; 22 : 49-55.
 
9) Hirai S, Naito M, Kuramasu M, et al. Low-dose exposure to di- (2-ethylhexyl) phthalate (DEHP) increases susceptibility to testicular autoimmunity in mice. Reprod Biol. 2015 ; 15 : 163-71.
 
P.245 掲載の参考文献
1) Isojima S, Tsuchiya K, Koyama K, et al. Further studies on sperm-immobilizing antibody found in sera of unexplained cases of sterility in women. Am J Reprod Immunol. 1972 ; 112 : 199-207.
 
2) World Health Organization : WHO laboratory manual for the examination and processing of human semen. 5th ed. 2010.
 
3) Bronson R, Cooper G, Rosenteld D. Ability of antibody-bound human sperm to penetrate zona-free hamster ova in vitro. Fertil Steril. 1981 ; 36 : 778-83.
 
4) Meinetz H, Bronson R. Detection of antisperm antibodies on the surface of motile spermatozoa. Comparison of the immunobead binding technique (IBT) and the mixed antiglobulin reaction (MAR). Am J Reprod Immunol Microbiol. 1988 ; 18 : 120-3.
 
5) Centola GM, Andolina E, Deutsch A. Comparison of the immunobead binding test (IBT) and immunospheres (IS) assay for detecting serum antisperm antibodies. Am J Reprod Immunol. 1997 ; 37 : 300-3.
PubMed
6) Shibahara H, Shiraishi Y, Hirono Y, et al. Diversity of the inhibitory effects on fertilization by anti-sperm antibodies bound to the surface of ejaculated human sperm. Hum Reprod. 2003 ; 18 : 1469-73.
 
7) Shibahara H, Hirono Y, Takamizawa S, et al. Effects of sperm-immobilizing antibodies bound to the surface of ejaculated human spermatozoa on sperm motility in immunologically infertile men. Fertil Steril. 2003 ; 79 : 641-2.
 
8) Koriyama J, Shibahara H, Ikeda T, et al. Toward standardization of the cut-off value for the direct immunobead test using the postcoital test in immunologically infertile males. Reprod Med Biol. 2013 ; 12 : 21-5.
PubMed
9) Shibahara H, Tsunoda T, Taneichi A, et al. Diversity of antisperm antibodies bound to sperm surface in male immunological infertility. Am J Reprod Immunol. 2002 ; 47 : 146-50.
PubMed
10) Naaby-Hansen S, Flickinger CJ, Herr JC. Two-dimensional gel electrophoretic analysis of vectorially labeled surface proteins of human spermatozoa. Biol Reprod. 1997 ; 56 : 771-87.
PubMed
11) Shibahara H, Sato I, Shotty J, et al. Two-dimensional electrophoretic analysis of sperm antigens recognized by sperm immobilizing antibodies detected in infertile women. J Reprod Immunol. 2002 : 53 : 1-12.
 
12) Shibahara H, Shiraishi Y, Suzuki M. Diagnosis and treatment of immunologically infertile males with antisperm antibodies. Reprod Med Biol. 2005 ; 4 : 133-41.
PubMed
13) Nagy ZP, Verheyen G, Lui J, et al. Results of 55 intracytoplasmic sperm injection cycles in the treatment of male-immunological infertility. Hum Reprod. 1995 ; 10 : 1775-80.
 
P.250 掲載の参考文献
1) Smith G. Cellular changes from graded testicular ischemia. J Urol. 1955 ; 73 : 355-62.
 
2) Thomas WEG, Crane GA, Cooper MJ, et al. Testicular exocrine malfunction after torsion. Lancet. 1984 ; 2 : 1357-60.
 
3) Visser AJ, Heys CF. Testicular function after torsion of the spermatic cord. BJU Int. 2003 ; 92 : 200-3.
 
4) Arap MA, Vicentini FC, Cocuzza M, et al. Late hormonal levels, semen parameters, and presence of antisperm antibodies in patients treated for testicular torsion. J Androl. 2007 ; 28 : 528-32.
 
5) Puri P, Barton D, O'Donnell B. Prepubertal testicular torsion : subsequent fertility. J Pediatr Surg. 1985 ; 20 : 598.
 
6) Gielchinsky I, Suraqui E, Hidas G, et al. Pregnancy rates after testicular torsion. J Urol. 2016 ; 196 : 852-5.
 
P.256 掲載の参考文献
1) Brinster R, Zimmermann J. Spermatogenesis following male germ cell transplantation. Proc Natl Acad Sci. 1994 ; 91 : 11298-302.
 
2) Clouthier D, Avarbock M, Maika S, et al. Rat spermatogenesis in mouse testis. Nature. 1996 ; 381 : 418-21.
 
3) Qu N, Naito M, Li J, et al. Xenogeneic and endogenous spermatogenesis following transplantation of rat germ cells into testes of immunocompetent mice. Reprod Fertil Dev. 2012 ; 24 : 337-43.
 
4) Shinohara T, Orwig KE, Avarbock MR, et al. Restoration of spermatogenesis in infertile mice by Sertoli cell transplantation. Biol Reprod. 2003 ; 68 : 1064-71.
 
5) Honaramooz A, Snedaker A, Boiani M, et al. Sperm from neonatal mammalian testes grafted in mice. Nature. 2002 ; 418 : 778-81.
 
6) Pullium JK, Milner R, Tuma GA, et al. Fertility after homologous prepubertal testis transplantation in the dog. Transplant Proc. 2008 ; 40 : 2744-9.
 
7) Yi K, Hatayama N, Hirai S, et al. Development of heterotopic transplantation of the testis with the epididymis to evaluate an aspect of testicular immunology in rats. PLoS One. 2017 ; 12 : e0177067.
 
8) Silber SJ. Transplantation of a human testis for anorchia. Fertil Steril. 1978 ; 30 : 181-7.
 
P.262 掲載の参考文献
1) Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy : systematic review and meta-analysis. AIDS. 2009 ; 23 : 1397-404.
PubMed
2) Supervie V, Viard JP, Costagliola D, et al. Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy : systematic review and bayesian modeling. Clin Infect Dis. 2014 ; 59 : 115-22.
PubMed
3) Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy : a prospective cohort analysis. Lancet. 2010 ; 375 : 2092-8.
PubMed
4) Ferraretto X, Estellat C, Damond F, et al. Timing of intermittent seminal HIV-1 RNA shedding in patients with undetectable plasma viral load under combination antiretroviral therapy. PLoS One. 2014 ; 9 : e88922.
PubMed
5) Fertility problems : assessment and treatment. Nice Guideline. <https://www.nice.org.uk/guidance/cg156/ifp/chapter/hiv-hepatitis-b-andhepatitis-c#couples-where-the-man-is-hiv-positive> (Accessed May 23rd, 2017)
 
6) Centers for Disease control and prevention. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. p.B16-23 <https://stacks.cdc.gov/view/cdc/7384> (Accessed May 23rd, 2017)
 
7) Ethics Committee of American Society for Reproductive Medicine. Human immunodeficiency virus (HIV) and infertility treatment : a committee opinion. Fertil Steril. 2015 ; 104 : e1-8.
 
8) 花房秀次. 体外受精における医学的情報とHIV感染者の挙児希望への対応. In : 山本政弘, 編. HIV感染者の挙児希望にかかるカウンセリングガイドライン. HIV感染症の医療体制の整備に関する研究班. 2015 (平成27) 年3月.
 
9) Savasi V, Ferrazzi E, Lanzani C, et al. Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples. Hum Reprod. 2007 ; 22 : 772-7.
 
10) Chu MC, Pena JE, Thornton MH 2nd, et al. Assessing the treatment efficacy of IVF with intracytoplasmic sperm injection in human immunodeficiency virus-1 (HIV-1) serodiscordant couples. Reprod Biomed Online. 2005 ; 10 : 130-4.
 
11) Sauer MV, Wang JG, Douglas NC, et al. Providing fertility care to men seropositive for human immunodeficiency virus : reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril. 2009 ; 91 : 2455-60.
 
12) 久慈直昭, 上條慎太郎, 井上治, 他. HIV患者男性に対する生殖医療. 産婦人科の実際. 2013 ; 62 : 499-506.
 
13) Inoue O, Kuji N, Ito H, et al. Clinical efficacy of a combination of Percoll continuous density gradient and swim-up techniques for semen processing in HIV-1 serodiscordant couples. Asian J Androl. 2017 ; 19 : 208-13.
 
14) Bujan L, Sergerie M, Moinard N, et al. Decreased semen volume and spermatozoa motility in HIV-1-infected patients under antiretroviral treatment. J Androl. 2007 ; 28 : 444-52.
PubMed
P.268 掲載の参考文献
1) Oosterlynck DJ, Konincky PR. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril. 1991 ; 56 : 45-51.
 
2) Moretta A, Sivori S, Vitale M, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Me. 1995 ; 182 : 875-4.
 
3) Maeda N, Izumiya C, Fukaya T, et al. Killer inhibitory receptor CD158a overexpression among natural killer cells in women with endometriosis is undiminished by laparoscopic surgery and gonadotropin releasing hormone agonist treatment. AJRI. 2004 ; 51 : 364-1.
 
4) Matsuoka S, Maeda N, Izumiya C, et al. Expression of inhibitory-motif killer immunoglobulin-like receptor, KIR2DL1, is increased in natural killer cells from women with pelvic endometriosis. AJRI. 2005 ; 53 : 249-54.
 
5) Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990 ; 248 : 220-3.
PubMed
6) Chang C, Murphy SP, Fervone S, et al. Differential in vivo and in vitro HLA-G expression in melanoma cells : potential mechanisms. Hum Immunol. 2003 ; 64 : 1057-63. Review.
 
7) Barrier BF, Kendall BS, Sharpe-Timmis KL, et al. HLA-G is expressed by the glandular epithelium of peritoneal endometriosis but not in eutopic endometrium. Hum Reprod. 2006 ; 21 : 864-9.
 
8) Kawashima M, Maeda, N, Izumiya C, et al. Human leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is expressed by eutopic endometrium only in the menstrual phase. Fertil Steril. 2009 ; 91 : 343-9.
 
9) Goodridge JP, Witt CS, Christiansen FT, et al. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J Immunol. 2003 ; 171 : 1768-74.
 
10) Kusume T, Maeda N, Izumiya C, et al. Human leukocyte antigen expression by peritoneal macrophages from women with pelvic endometriosis is depressed but coordinated with costimulatory molecule expression. Fertil Steril. 2005 ; 83 Suppl 1 : 1232-40.
 
11) Yamamoto Y, Maeda N, Izumiya C, et al. Decreased human leukocyte antigen-DR expression in the lipid raft by peritoneal macrophages from women with endometriosis. Fertil Steril. 2008 ; 89 : 52-9.
 
12) Nowak I, Ploski R, Barcz E, et al. KIR2DS5 in the presence of HLA-C C2 protects against endometriosis. Immunogenetics. 2015 ; 67 : 203-9.
 
13) Galandrini R, Porpora MG, Stoppacciaro A. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis. Fertil Steril. 2008 ; 89 (5 Suppl) : 1490-6.
 
14) Gonzalez-Foruria I, Santulli P, Chouzenoux S, et al. Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity. PLoS One. 2015 ; 10 : eo119961.
 
P.273 掲載の参考文献
1) Harada T, Iwabe T, Terakawa N, et al. Role of cytokine in endometriosis. Fertil Steril. 2001 ; 7 : 665-70.
 
2) Yoshida S, Harada T, Lwabe T, et al. A combination of interleukin-6 and its soluble receptor impairs sperm motility : implications in infertility associated with endometriosis. Hun Reprod. 2004 ; 19 : 1821-5.
 
3) Sakamoto Y, Harada T, Horie S, et al. Tumor necrosis factor-α-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through NF-κB activation : gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab. 2003 ; 88 : 730-5.
 
4) Takenaka Y, Taniguchi F, Miyakoda H, et al. Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2 expression. Fertil Steril. 2010 ; 93 : 325-7.
 
5) Uegaki T, Taniguchi F, Nakamura K, et al. Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis. Hum Reprod. 2015 ; 30 : 149-58.
 
6) Taniguchi F, Higaki H, Izawa M, et al. The cellular inhibitor of apoptosis protein-2 is a possible target of novel treatment for endometriosis. Am J Reprod Immunol. 2014 ; 71 : 278-85.
 
P.279 掲載の参考文献
1) Oosterlynck DJ, Meuleman C, Waer M. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. Fertil Steril. 1992 ; 58 : 290-5.
 
2) Ho HN, Wu MY, Yang YS. Peritoneal cellular immunity and endometriosis. Am J Reprod Immunol. 1997 ; 38 : 400-12.
 
3) Funamizu A, Fukui A, Kamoi M, et al. Expression of natural cytotoxicity receptors on peritoneal fluid natural killer cell and cytokine production by peritoneal fluid natural killer cell in women with endometriosis. Am J Reprod Immunol. 2014 ; 71 : 359-67.
 
4) Ho HN, Chao KH, Chen HF. Peritoneal natural killer cytotoxicity and CD25+ CD3+lymphocyte subpopulation are decreased in women with stage III-IV endometriosis. Hum Reprod. 1995 ; 10 : 2671-5.
 
5) Zhang C, Maeda N, Izumiya C, et al. Killer immunoglobulin-like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. Am J Reprod Immunol. 2006 ; 55 : 106-14.
 
6) Kopcow HD, Allan DS, Chen X, et al. Human decidual NK cells form immature activating synapses and are not cytotoxic. Proc Natl Acad Sci USA. 2005 ; 102 : 15563-8.
 
7) El Costa H, Tabiasco J, Berrebi A, et al. Effector functions of human decidual NK cells in healthy early pregnancy are dependent on the specific engagement of natural cytotoxicity receptors. J Reprod Immunol. 2009 ; 82 : 142-7.
 
8) Fukui A, Ntrivalas E, Gilman-Sachs A, et al. Expression of natural cytotoxicity receptors and a2V-ATPase on peripheral blood NK cell subsets in women with recurrent spontaneous abortions and implantation failures. Am J Reprod Immunol. 2006 ; 56 : 312-20.
PubMed
9) Fukui A, Funamizu A, Fukuhara R, et al. The expression of natural cytotoxicity receptors (NCRs) and cytokine production on endometrial natural killer (NK) cells in women with recurrent pregnancy loss (RPL) or implantation failure, and the expression of NCRs on peripheral blood NK cells in pregnant women with a history of RPL. J Obstet Gynaecol Res. 2017.
 
10) Yokota M, Fukui A, Funamizu A, et al. Role of NKp46 expression in cytokine production by CD56-positive NK cells in the peripheral blood and the uterine endometrium. Am J Reprod Immunol. 2013 ; 69 : 202-11.
PubMed
11) Ghadially H, Horani A, Glasner A, et al. NKp46 regulates allergic responses. Eur J Immunol. 2013 ; 43 : 3006-16.
 
12) Giuliani E, Parkin KL, Lessey BA, et al. Characterization of uterine NK cells in women with infertility or recurrent pregnancy loss and associated endometriosis. Am J Reprod Immunol. 2014 ; 72 : 262-9.
 
P.285 掲載の参考文献
1) Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis., Fertil Steril, 2001 ; 76 : 1-10.
 
2) Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995 ; 155 : 1151-64.
 
3) Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003 ; 299 : 1057-61.
 
4) 坂口志文. 第7章 C 免疫制御のメカニズム (制御性T細胞). In : 谷口克, 監. 標準免疫学 第3版. 東京 : 医学書院 ; 2013.
 
5) Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+T cells expressing the FoxP3 transcription factor. Immunity. 2009 ; 30 : 899-911.
 
6) Berbic M, Hey-Cunningham AJ, Ng C, et al. The role of Foxp3+regulatory T-cells in endometriosis : a potential controlling mechanism for a complex, chronic immunological condition. Hum Reprod. 2010 ; 25 : 900-7.
 
7) Tanaka Y, Mori T, Ito F, et al. Exacerbation of endometriosis due to regulatory T cell dysfunction. J Clin Endocrinol Metab. 2017. 102 : 3206-17.
 
P.290 掲載の参考文献
1) Ota H, Igarashi S, Sasaki M, et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Human reproduction. 2001 ; 16 : 561-6.
 
2) Chishima F, Hayakawa S, Sugita K, et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol. 2002 ; 48 : 50-6.
 
3) Chishima F, Hayakawa S, Yamamoto T, et al. Expression of inducible microsomal prostaglandin E synthase in local lesions of endometriosis patients. Am J Reprod Immunol. 2007 ; 57 : 218-26
 
4) Burke SD, Barrette VF, Gravel J, et al. Uterine NK cells, spiral artery modification and the regulation of blood pressure during mouse pregnancy. Am J Reprod Immunol. 2010 ; 63 : 472-81.
 
5) Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989 ; 163 : 284-91.
 
6) Abraham F, Sacerdoti F, De Leon R, et al. Angiotensin II activates the calcineurin/NFAT signaling pathway and induces cyclooxygenase-2 expression in rat endometrial stromal cells. PloS one. 2012 ; 7 : e37750.
 
7) Nakao T, Chishima F, Sugitani M, et al. Expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in endometriotic lesions. Gynecol Obstet Invest. 2017 ; 82 : 294-302.
 
8) Nenicu A, Korbel C, Gu Y, et al. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-gamma by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Hum Reprod. 2014 ; 29 : 1011-24.
 
9) Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin- (1-7) -MAS receptor axis : more than regulation of blood pressure? Hypertension. 2007 ; 50 : 596-9.
 
10) Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Nat Acad Sci USA. 2003 ; 100 : 8258-63.
 
P.295 掲載の参考文献
1) Kim BG, Yoo JY, Kim TH, et al. Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis. Hum Reprod. 2015 ; 30 : 1069-78.
 
2) Yoo JY, Jeong JW, Fazleabas AT, et al. Protein inhibitor of activated STAT3 (PIAS3) is down-regulated in eutopic endometrium of women with endometriosis. Biol Rprod. 2016 ; 95 : 1-7.
 
3) Itoh F, Komohara Y, Kakaishi K, et al. Possible involvement of signal transducer and activator of transcription-3 in cell-cell interactions of peritoneal macrophages and endometrial stromal cells in human endometriosis. Fertil Steril. 2013 ; 99 : 1705-13.
 
4) Okamoto M, Nasu K, Abe W, et al. Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3. Hum Reprod. 2015 ; 30 : 632-41.
 
P.302 掲載の参考文献
1) 藤原寛行, 今野良, 根津幸穂, 他. 子宮内膜症の適切な治療法選択 疼痛に対する治療法の選択 ロイコトリエン受容体拮抗剤を中心として月経困難症に対するロイコトリエン受容体拮抗剤 (モンテルカスト) の有用性の検討. 産婦人科の実際. 2009 ; 58 : 1125-30.
 
2) 根津幸穂, 今野良, 藤原寛行, 他. 子宮内膜症の新しい治療戦略-抗ロイコトリエン受容体拮抗薬-産婦人科の世界. 2006 ; 58 : 629-35.
 
3) Martin TR, Altman LC, Albert RK, et al. Leukotriene B4 production by the human alveolar macrophage : a potential mechanism for amplifying inflammation in the lung. Am Rev Respir. 1984 ; 129 : 106-11.
 
4) Rees MC, DiMarzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol. 1987 ; 113 : 291-5.
 
5) Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol. 1989 ; 3 : 71-94.
 
6) Bieglmayer C, Hofer G, Kainz C, et al. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 1995 ; 9 : 307-12.
 
7) Chegini N, Rao CV. The presence of leukotriene C4- and prostacyclin-binding sites in nonpregnant human uterine tissue. J Clin Endocrinol Metab. 1988 ; 66 : 76-87.
 
8) 根津幸穂, 藤原寛行, 今野良. 子宮内膜症の新しい治療法. 金澤康徳他, 編. Annual Review 糖尿病・代謝・内分泌. 生殖医学 B 臨床分野での進歩. 東京 : 中外医学社. 2008 ; 215-21.
 
9) 矢野哲. 子宮内膜症の疼痛管理. Prog. Med. 29. 2009 ; 1767-75.
 
10) Nigam SC, Leo-Rossberg I, et al. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoid 1991 ; 4 : 137-41.
 
11) Rees MC, Anderson AB, Demers LM, et al. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhea. Br J Obstet Gynaecol. 1984 ; 91 : 673-80.
 
12) Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol. 1990 ; 97 : 588-94.
 
13) Hofer G, Bieglmayer C, Kopp B, et al. Measurement of eicosanoids in menstrual fluid by the combined use of high pressure chromatography and radioimmunoassay. Prostaglandins. 1993 ; 45 : 413-26.
 
14) Harel Z, Lilly C, Riggs S, et al. Urinary leukotriene (LT) E (4) in adolescents with dysmenorrhea : a pilot study. J Adolesc Health. 2000 ; 27 : 151-4.
 
15) Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril. 2001 ; 76 : 1-10.
 
16) Fakih H, Baggett B, Holtz G, et al. Interleukin-1 : a possible role in the infertility associated with endometriosis. Fertil Steril. 1987 ; 47 : 213-7.
 
17) Taketani Y, Kuo TM, Mizuno M. Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis. Am J Obstet Gynecol. 1992 ; 167 : 265-70.
 
18) Abu JI, Konje JC. Leukotrienes in gynaecology : the hypothetical value of anti-leukotriene therapy in dysmenorrhoea and endometriosis. Hum Reprod Update ; 2000 ; 6 : 200-5.
 
19) Carraher R, Hahn DW, Ritchie DM, et al. Involvement of lipoxygenase products in myometrial contractions. Prostaglandins. 1983 ; 26 : 23-32.
 
20) Uchiide I, Ihara T, Sugamata M. Pathological evaluation of the rat endometriosis model. Fertil Steril. 2002 ; 78 : 782-6.
 
21) Ihara T, Uchiide I, Sugamata M. Light and electron microscopic evaluation of antileukotriene therapy for experimental rat endometriosis. Fertil Steril. 2004 ; 81 (Suppl) 1 : 819-23.
 
22) Matsuzaki S, Canis M, Darcha C, et al. Increased mast cell density in peritoneal endometriosis compared with eutopic endometrium with endometriosis. Am J Reprod Immunol. 1998 ; 40 : 291-4.
 
23) Osuga Y, Koga K, Tsutsumi O, et al. Stem cell factor (SCF) concentrations in peritoneal fluid of women with or without endometriosis. Am J Reprod Immunol. 2000 ; 44 : 231-5.
 
24) Fujiwara H, Konno R, Netsu S, et al. Localization of mast cells in endometrial cysts. Am J Reprod Immunol. 2004 ; 51 : 341-4.
 
25) Konno R, Yamada-Okabe H, Fujiwara H, et al. Role of immunoreactions and mast cells in pathogenesis of human endometriosis--morphologic study and gene expression analysis. Hum Cell. 2003 ; 16 : 141-9.
 
26) Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol. 2007 ; 119 : 618-25.
 
27) Harel Z, Riggs S, Vaz R, et al. The use of the leukotriene receptor antagonist montelukast (Singulair) in the management of dysmenorrhea in adolescents. J Pediatr Adolesc Gynecol. 2004 ; 17 : 183-6.
 
28) Konno R, Fujiwara H, Suzuki M. Effectiveness of leukotriene receptor antagonists for dysmenorrhea of en dometriosis. Fam Med. 2004 ; 36 : 8-9.〔根津幸穂, 今野良, 藤原寛行, 他. 子宮内膜症の新しい治療戦略-抗ロイコトリエン受容体拮抗薬-産婦人科の世界. 2006 ; 58 : 629-35〕.
 
29) 根津幸穂, 藤原寛行, 今野 良, 他. 子宮内膜症の新しい考え方. ロイコトリエン受容体拮抗薬による治療. 産と婦. 2008 ; 75 : 21-5.
 
30) 今野良, 根津幸穂, 小田切幸平, 他. 子宮内膜症の薬物療法. 臨床応用が期待される薬物療法 (1) ロイコトリエン受容体拮抗薬-子宮内膜症の痛みと慢性炎症を抑制する機序-. Hormone Frontier Gynecol. 2007 ; 14 : 347-56.
 
31) 菅又昌雄, 井原智美, 内出一郎. 抗アレルギー剤療法. 特にロイコトリエン受容体拮抗剤療法の病理学的評価. Medical ASAHI. 2003 ; 80-3.
 
32) 藤原豊博. ロイコトリエン受容体拮抗薬の適応外使用. 薬理と治療. 2012 ; 40 : 933-39.
 
P.310 掲載の参考文献
1) Nnoaham KE, Hummelshoj L, Webster P, et al. World Endometriosis Research Foundation Global Study of Women's Health Consortium. Impact of endometriosis on quality of life and work productivity : a multicenter study across ten countries. Fertil Steril. 2011 ; 96 : 366-73.
 
2) D'Hooghe TM, Debrock S. Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Hum Reprod Update. 2002 ; 8 : 84-8.
 
3) Kennedy S, Bergqvist A, Chapron C, et al. on Behalf of the ESHRE Special Interest Group for Endometriosis Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005 ; 20 : 2698-704.
 
4) Yang WC, Chen HW, Au HK, et al. Serum and endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2004 ; 18 : 305-18.
 
5) 奥久人, 辻芳之, 香山浩二. 子宮内膜症の病態形成のKey FactorとしてのIL-18. 産婦人科の実際. 2003 ; 52 : 229-32.
 
6) Harada T, Yoshioka H, Yoshida S, et al. Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am J Obstet Gynecol. 1997 ; 176 : 593-7.
 
7) 北脇城. 子宮内膜症の診断精度向上をめざして. K-ネットカンファレンス. 2002.
 
8) Mathur S, Peress MR, Williamson HO, et al. Autoimmunity to endometrium and ovary in endometriosis. Clin Exp Immunol. 1982 ; 50 : 259-66.
 
9) Nabeta M, Abe Y, Haraguchi R, et al. Serum anti-PDIK1L autoantibody as a novel marker for endometriosis. Fertil Steril. 2010 ; 94 : 2552-7.
 
10) Nabeta M, Abe Y, Takaoka Y, et al. Identification of anti-Syntaxin 5 autoantibody as a novel endometriotic marker. J Reprod Immuno. 2011 ; 91 : 48-55.
 
11) Guo L, Ji C, Gu S, et al. Molecular cloning and characterization of a novel human kinase gene, PDIK1L. J Genet. 2003 ; 82 : 27-32.
 
12) Somigliana E, Vigano P, Tirelli A, et al. Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Hum Reprod. 2004 ; 19 : 1871-6.
 
P.322 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement of an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295-306.
 
2) Sugiura-Ogasawara M, Suzuki S, Ozaki Y, et al. Frequency of recurrent spontaneous abortion and its influence on further marital relationship and illness : The Okazaki Cohort Study in Japan. J Obstet Gynaecol Res. 2013 ; 39 : 126-31.
 
3) Sugiura-Ogasawara M, Ozaki Y, Kitaori T, et al. Midline uterine defect size correlated with miscarriage of euploid embryos in recurrent cases. Fertil Steril. 2010 ; 93 : 1983-8.
 
4) Branch DW, Gibson M, Silver RM. Clinical Practice : Recurrent miscarriage. N Engl J Med. 2010 ; 363 : 1740-7.
 
5) Sugiura-Ogasawara M, Ozaki Y, Katano K, et al. Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod. 2012 ; 27 : 2297-303.
PubMed
6) Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010 ; 376 : 1498-509.
 
7) 平成27年度日本医療研究開発機構成育疾患克服等総合研究事業「抗リン脂質抗体症候群合併妊娠の治療及び予後に関する研究」研究班. 抗リン脂質抗体症候群合併妊娠の診療ガイドライン. 東京 : 南山堂 ; 2016.
 
8) Rand JH, Wu X, Anderee HAM, et al. Pregnancy loss in the antiphospholipid antibody syndrome -a possible thrombogenic mechanism. N Engl J Med. 1997 ; 337 : 154-60.
 
9) Quenby S, Mountfield S, Chamley L, et al. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril. 2005 ; 83 : 691-8.
 
10) Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004 ; 10 : 1222-6.
 
11) Tanimura K, Jin H, Suenaga T, et al. β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood. 2015 ; 125 : 2835-44.
 
12) Pengo V, Tripodi A, Reber G, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009 ; 7 : 1737-40.
 
13) Katano K, Aoki K, Sasa H, et al. beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod. 1996 ; 11 : 509-12.
 
14) Ogasawara MS, Aoki K, Katano K, et al. Factor XII but not protein C, protein S, antithrombin III or factor XIII as a predictor of recurrent miscarriage. Fertil Steril. 2001 ; 75 : 916-9.
 
15) Kitaori T, Sugiura-Ogasawara M, Oku K, et al. Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome. Lupus. 2015 ; 24 : 1505-19.
 
16) Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012 ; 64 : 2311-8.
 
17) Clark CA, Davidovits J, Spitzer KA, et al. The lupus anticoagulant : results from 2257 patients attending a high-risk pregnancy clinic. Blood. 2013 ; 122 : 341-7.
 
18) Ogasawara M, Aoki K, Kajiura S, et al. Are antinuclear antibodies predictive of recurrent miscarriage? Lancet. 1996 ; 347 : 1183-4.
 
19) Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phopholipid antibodies (or antiphospholipid antibodies). BMJ. 1997 ; 314 : 253-7.
 
20) Kutteh WH. Antiphospholipid antibodies-associated recurrent pregnancy loss : treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996 ; 174 : 1584-89.
 
21) Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss : a systematic review and meta-analysis. Obstet Gynecol. 2010 ; 115 : 1256-62.
 
22) Askie LM, Duley L, Henderson-Smart DJ, et al : PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia : a meta-analysis of individual patient data. Lancet. 2007 ; 369 : 1791-8.
 
23) Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010 ; 362, 1586-96.
 
24) Sugiura-Ogasawara M, Omae Y, Kawashima M, et al. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet. 2017. doi : 10.1038
 
25) Sugiura-Ogasawara M, Atsumi T, Yamada H, et al. Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies. Modern Rheumatol. 2015 ; 30 : 1-22
 
P.330 掲載の参考文献
1) Robertson L, Wu O, Langhorne P, et al. Thrombosis : Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy : a systematic review. Br J Haematol. 2006 ; 132 : 171-96.
 
2) Rodger MA, Carrier M, Le Gal G, et al. Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014 ; 123 : 822-8.
 
3) Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications : which path for the journey to precision medicine? Br J Haematol. 2014 ; 165 : 585-99.
 
4) Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update. 2008 ; 14 : 623-45.
 
5) Reznikoff-Etievan MF, Cayol V, Carbonne B, et al. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG. 2001 ; 108 : 1251-4.
 
6) Pabinger I, Nemes L, Rintelen C, et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J. 2000 ; 1 : 37-41.
 
7) 齋藤滋, 杉浦真弓, 田中忠夫, 他. 本邦における不育症のリスク因子とその予後に関する研究. 日本周産期・新生児医学会雑誌. 2009 ; 45 : 1144-8.
Medical*Online
8) Ebina Y, Ieko M, Naito S, et al. Low levels of plasma protein S, protein C and coagulation factor XII during early pregnancy and adverse pregnancy outcome. Thromb Haemost. 2015 ; 114 : 65-9.
 
9) Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss : a meta-analysis. Lancet. 2003 ; 361 : 901-8.
 
10) Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004 ; 103 : 3695-9.
 
11) Shinozaki N, Ebina Y, Deguchi M, et al. Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. Gynecol Endocrinol. 2016 β ; 32 : 672-4.
 
12) Pauer HU, Burfeind P, Kostering H, et al. Factor XII deficiency is strongly associated with primary recurrent abortions. Fertil Steril. 2003 ; 80 : 590-4.
 
13) Matsuura T, Kobayashi T, Asahina T, et al. Is factor XII deficiency related to recurrent miscarriage? Semin Thromb Hemost. 2001 ; 27 : 115-20.
 
14) Inomo A, Sugi T, Fujita Y, et al. The antigenic binding sites of autoantibodies to factor XII in patients with recurrent pregnancy losses. Thromb Haemost. 2008 ; 99 : 316-23.
 
15) Ogasawara MS, Iinuma Y, Aoki K, et al. Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII. Fertil Steril. 2001 ; 76 : 203-4.
PubMed
16) Qublan H, Amarin Z, Dabbas M, et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia : a prospective randomized placebo-controlled trial. Hum Fertil (Camb). 2008 ; 11 : 246-53.
 
17) Steinvil A, Raz R, Berliner S, et al. Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost. 2012 ; 108 : 1192-7.
 
P.335 掲載の参考文献
1) 平澤正夫. 超薬アスピリン スーパードラッグへの道. 東京 : 平凡社 ; 2001.
 
2) Francesca CL, Muredach PR, Shiv CK, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Ehgl J Med. 2001 ; 345 : 1809-17.
 
3) Sugiura-Ogasawara M, Ozaki Y, Nakanishi T, et al. Occasional antiphospholipid antibody positive patients with recurrent pregnancy loss also merit aspirin therapy : a retrospective cohort-control study. Am J Reprod Immunol. 2008 ; 59 : 235-41.
PubMed
4) 日本産科婦人科学会・日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2017. 2017.
 
5) Schisterman EF, et al. Preconception low-dose aspirin and pregnancy outcomes : results from the EAGeR randomized trial. Lancet. 2014 ; 384 : 29-36.
 
P.340 掲載の参考文献
1) 日本産科婦人科学会・日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2017. 2017.
 
2) Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995 ; 10 : 3301-4.
 
3) Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss : a systematic review and meta-analysis. Obstet Gynecol. 2010 ; 115 : 1256-62.
 
4) Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995 ; 332 : 1330-5.
 
5) Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006 ; 4 : 759-65.
 
P.344 掲載の参考文献
1) 日本産科婦人科学会・日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2017. 2017.
 
2) 山本一彦, 編. ステロイド薬の選び方・使い方ハンドブック. 東京 : 羊土社 ; 2008.
 
3) Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003 ; 361 : 1881-93.
PubMed
4) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement of update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295-306.
 
5) Rai R, Regan L. Recurrent miscarriage. Lancet. 2006 ; 368 : 601-11.
 
P.348 掲載の参考文献
1) 齋藤滋, 他. 本邦における不育症リスク因子とその予後に関する研究 厚生労働科学研究費補助金成育疾患克服等次世代育成基盤研究事業 不育症に関する再評価と新たなる治療法の開発に関する研究. 平成20年度～22年度総合研究報告書. 2011. p.53.
 
2) Coulam CB, Krysa L, Stern JJ, et al. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol. 1995 ; 34 : 333-7.
PubMed
3) The Practice Committee of the American Society for Reproductive Medicine : Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss. Fertil Steril. 2006 ; 86 : S226-7.
 
4) Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage : a systematic review. BJOG. 2007 ; 114 : 134-42.
 
5) Ata B, Tan SL, Shehata F, et al. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. Fertil Steril. 2011 ; 95 : 1080-5. e1-2.
 
6) Christiansen O, Larsen EC, Egerup P, et al. Intravenous immunoglobulin treatment for secondary recurrent miscarriage : a randomised, double-blind, placebo-controlled trial. BJOG. 2015 ; 122 : 500-8.
 
7) Yamada H, Kishida T, Kobayashi N, et al. Massive immunoglobulin treatment in women with four or more recurrent spontaneous primary abortions due to unexplained aetiology. Hum Reprod. 1998 ; 13 : 2620-3.
PubMed
8) Yamada H, Takeda M, Maezawa Y, et al. A high dose intravenous immunoglobulin therapy for women with four or more recurrent spontaneous abortions. ISRN Obstet Gynecol. 2012 ; doi : 10. 5402/2012/512732, 1-5.
 
P.352 掲載の参考文献
1) Kaandorp S, Di Nisio M, Goddijn M, et al. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. The Cochrane database of systematic reviews. 2009 : Cd004734.
 
2) Schleussner E, Kamin G, Seliger G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss : a multicenter trial with a minimization randomization scheme. Annals of internal medicine. 2015 ; 162 : 601-9.
 
3) Mekinian A, Cohen J, Alijotas-Reig J, et al. Unexplained recurrent miscarriage and recurrent implantation failure : Is there a place for immunomodulation? Am J Reprod Immunol. 2016 ; 76 : 8-28.
 
4) Roussev RG, Acacio B, Ng SC. Duration of intralipid's suppressive effect on NK cell's functional activity. Am J Reprod Immunol. 2008 ; 60 : 258-63.
 
5) Meng L, Lin J, Chen L, et al. Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion. Arch Gynecol Obstet. 2016 ; 294 : 29-39.
PubMed
6) Dakhly DM, Bayoumi YA, Sharkawy M, et al. Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells. Int J Gynaecol Obstet. 2016 ; 135 : 324-7.
PubMed
7) Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol. 2012 ; 67 : 296-304.
PubMed
8) Hviid MM, Macklon N. Immune modulation treatments-where is the evidence? Fertil Steril. 2017 ; 107 : 1284-93.
PubMed
P.356 掲載の参考文献
1) Kanauchi H, Imamura S, Takigawa M, et al. Evaluation of the Japanese-Chinese herbal medicine, kampo, for the treatment of lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. J Dermatol. 1994 ; 21 : 935-9.
 
2) Nakano Y, Suda T, Tozawa F, et al. Sairei-to (a Chinese herbal drug) -stimulated secretion and synthesis of pituitary ACTH are mediated by hypothalamic corticotrophin-releasing factor. Neurosci Lett. 1993 ; 160 : 93-5.
 
3) Yasuda M, Takakuwa K, Tokunaga A, et al. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995 ; 86 : 555-9.
 
4) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphopholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295-306.
 
5) Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986 ; 13 : 486-91.
 
6) Lubbe WF, Butler WS, Palmer SJ, et al. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1983 ; 1 : 1361-3.
PubMed
7) Branch DW, Scott JR, Kochenour NK, et al. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985 ; 313 : 1322-6.
 
8) Hasegawa I, Takakuwa K, Goto S, et al. Effectiveness of predonisolone/aspirin therapy for recurrent aborters with antiphospholipid antibodies. Hum Reprod. 1992 ; 7 : 203-7.
 
9) Keeling D, Mackie I, Moore GW, et al. Guideline on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 ; 157 : 47-58.
 
10) Arakawa M, Takakuwa K, Honda K, et al. Suppressive effect of anticardiolipin antibody on the proliferation of human umbilical vein endothelial cells. Fertil Steril. 1999 ; 71 : 1103-7.
 
11) Ichikawa G, Yamamoto T, Chishima F, et al. Effect of anti-β2-glycoprotein I antibody on PIGF, VEGF and sVEGFR1 production from cultured choriocarcinoma cell line. J Obstet Gynaecol Res. 2011 ; 37 : 1076-83.
 
12) Takakuwa K, Yasuda M, Hataya I, et al. Treatment for patients with recurrent abortion with positive antiphospholipid antibodies using a traditional Chinese herbal medicine. J Perin Med. 1996 ; 24 : 489-94.
 
13) Takakuwa K, Ooki I, Nonaka T, et al. Prophylactic therapy for patients with reproductive failure who were positive for anti-phospholipid antibodies. Am J Reprod Immunol. 2006 ; 56 : 237-42.
 
P.361 掲載の参考文献
1) Saito S, Shima T, Nakashima A, et al. Role of paterhal antigen-specific Treg cells in Am J Reprod Immunol. 2016 ; 75 : 310-6.
 
2) DeLuca HF, Cantorna MT. Vitamin D : its role and uses in immunology. FASEB J. 2001 ; 15 2579-85.
 
3) Liu PT. Stenger S, LiH, et al. Toll-like receptor triggerng of a Vitamin D-medliated human anti icrobial response. Science. 2006 ; 311 : 1770.
 
4) Mora JR, Iwata M, von Andrian UH, Vitamin effects on the immnne system : Vitamin A and D take centre stage. Nat Rev Immunol. 2008 ; 8 : 685-98
 
5) Ji JL, Muyayalo KP, Zhang YH, et al. Immunological function of vitamin D during human pregnancy. Am J Reprod Immunol. 2017 ; 77 : e12620.
 
6) Ota K, Dambaeva S, Han AR, Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod. 2014 ; 29 : 208-19.
 
7) Ota K Dambaeva S, Kim MW, et al. 1,25-dihydroxy-Vitamin D3 regulates NK-cell cytotoxicity, cytokine secretion, and degranulation in women with recurrent pregnancy losses. Eur J Immunol. 2015 ; 45 : 3188-99.
 
8) Chen X, Yin B, Lian RC, et al. Modulatory effects of vitamin D on peripheral cellular immunity in patients with recurrent miscarriage. Am J Reprod Immunol. 2016 ; 76 : 432-8.
 
9) ESHRE不育症診療ガイドライン <http://www.eshre.en/Guidelines-and-legal.aspx>
 
P.366 掲載の参考文献
1) Wegmann TG. Placental immunotrophism : Maternal T cells enhance placental growth and function. Am J Reprod Immunol. 1987 ; 15 : 67-70.
 
2) Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today. 1997 ; 18 : 478-82.
 
3) Shima T, Inada K, Nakashima A, et al. Paternal antigen-specific proliferating regulatory T cells are increased in uterine-draining lymph nodes just before implantation and in pregnant uterus just after implantation by seminal plasma-priming in allogeneic mouse pregnancy. J Reprod Immunol. 2015 ; 108 : 72-82.
 
4) Beer AE, Quebbeman JF, Ayers JWT, et al. Major histocompatibility complex antigens, maternal and paternal immune responses, and chronic habitual abortions in humans. Am J Obstet Gynecol. 1981 ; 141 : 987-99.
 
5) Taylor C, Faulk WP. Prevention of recurrent abortion with leucocyte transfusions. Lancet. 1981 ; 2 : 68-70.
 
6) Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet. 1985 ; 1 : 941-3.
 
7) Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide collaborative observational study and metaanalysis on allogeneic leucocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol. 1994 ; 32 : 55-72.
 
8) Ober C, Karrison T, Odem RR, et al. Mononuclear cell immunisation in prevention of recurrent miscarriages : A randomized trial. Lancet. 1999 ; 354 : 365-9.
 
9) Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent abortion. Cochrane Database Syst Rev. 2006 ; (2) : CD000112.
 
10) Pandey MK, Agrawal S. Induction of MLR-Bf and protection of fetal loss : a current double blind randomized trial of paternal lymphocyte immunization for women with recurrent spontaneous abortion. Int Immunopharmacol. 2004 ; 4 : 289-98.
 
11) Liu Z, Xu H, Kang X, et al. Allogenic Lymphocyte Immunotherapy for Unexplained Recurrent Spontaneous Abortion : A Meta-Analysis. Am J Reprod Immunol. 2016 ; 76 : 443-53.
 
12) Cavalcante MB, Sarno M, Araujo Junior E, et al. Lymphocyte immunotherapy in the treatment of recurrent miscarriage : systematic review and meta-analysis. Arch Gynecol Obstet. 2017 ; 295 : 511-8.
 
13) Takakuwa K, Goto S, Tanaka K, et al. Result of immunotherapy on patients with unexplained recurrent abortion : A beneficial treatment for patients with negative blocking antibodies. Am J Reprod Immunol. 1990 ; 23 : 37-41.
 
14) Nonaka T, Takakuwa K, Ooki I, et al. Results of immunotherapy for patients with unexplained primary recurrent abortions-prospective non-randomized cohort study. Am J Reprod Immunol. 2007 ; 58 : 530-6.
 
15) Adachi H, Takakuwa K, Tanaka K, et al. Results of immunotherapy for patients with unexplained secondary recurrent abortion. Clin Immunol. 2003 ; 106 : 175-80.
 
P.371 掲載の参考文献
1) 山下道雄. タクロリムス (FK506) 開発物語. 生物工学. 2013 ; 91 : 142-54.
 
2) Briggs GG, Freedman RK, Editors. Drug in Pregnancy & Lactation, 10th ed. NY : Lippomcott Williams & Wilkins ; 2015 : p.1305-9.
 
3) Nevers W, Pupcp A, Koren G, et al. Safety of tacrolimus in pregnancy. Can Fam Physician. 2014 ; 60 : 905-6.
 
4) 萩原大二郎, 塩田浩平. プログラフの妊娠時使用経験. 今日の移植. 2004 ; 17 : 451-3.
 
5) 打田和治. プログラフ他施設間長期成績調査-長期7年間のまとめ-. 今日の移植. 2006 ; 19 : 380-9.
 
6) Uemura Y, Suzuki M, Liu TY, et al. Role of human non-invariant NKT lymphocytes in the maintenance of type 2 T helper environment during pregnancy. Int Immunol. 2008 ; 20 : 405-12.
 
7) Saito S, Nakashima A, Shima T, et al. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010 ; 63 : 601-10.
PubMed
8) Kwak-Kim JY, Chung-Bang HS, Ng SC, et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy lossess and in infertile women with multiple implantation failures after IVF. Hum Reprod. 2003 ; 18 : 767-73.
 
9) Nakagawa K, Kwak-Kim JY, Ohta K, et al. Immuno suppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood Th1/Th2 cell ratios. Am J Reprod Immunol. 2015 ; 73 : 353-61.
 
P.374 掲載の参考文献
1) Kwak-Kim J, Gilman-Sachs A. Clinical implication of natural killer cells and reproduction. Am J Reprod Immunol. 2008 ; 59 : 388-400.
 
2) Kwak-Kim JY, Chung-Bang HS, Ng SC, et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod. 2003 ; 18 : 767-73.
 
3) Kwak-Kim JY, Gilman-Sachs A, Kim CE. T helper 1 and 2 immune responses in relationship to pregnancy, nonpregnancy, recurrent spontaneous abortions and infertility of repeated implantation failures. Chem Immunol Allergy. 2005 ; 88 : 64-79.
 
4) Higuma-Myojo S, Sasaki Y, Miyazaki S. Cytokine profile of natural killer cells in early human pregnancy. Am J Reprod Immunol. 2005 ; 54 : 21-9.
 
5) Fukui A, Kwak-Kim J, Ntrivalas E, et al. Intracellular cytokine expression of peripheral blood natural killer cell subsets in women with recurrent spontaneous abortions and implantation failures. Fertil Steril. 2008 ; 89 : 157-65.
PubMed
6) Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005 ; 25 : 1181-92.
 
7) Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF) -alpha therapy. Rheumatology (Oxford). 2007 ; 46 : 695-8.
 
8) Hyrich KL, Symmons DP, Watson KD, et al, British Society fRBR, Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents : results from a national population register. Arthritis Rheum. 2006 ; 54 : 2701-2.
 
9) Komoto S, Motoya S, Nishiwaki Y, et al, Japanese study group for pregnant women with IBD. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy : a multicenter study from Japan. Intest Res. 2016 ; 14 : 139-45.
 
10) Komaki F, Komaki Y, Micic D, et al, Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-alpha use in females with immune mediated diseases ; a systematic review and meta-analysis. J Autoimmun. 2017 ; 76 : 38-52.
 
11) Verstappen SM, King Y, Watson KD, et al, Bsrbr Control Centre Consortium BSRBR. Anti-TNF therapies and pregnancy : outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011 ; 70 : 823-6.
 
12) Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol. 2008 ; 60 : 8-16.
PubMed
13) Winger EE, Reed JL, Ashoush S, et al. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009 ; 61 : 113-20.
PubMed
14) Clark DA. Should anti-TNF-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? Am J Reprod Immunol. 2009 ; 61 : 107-12.
 
15) Hviid MM, Macklon N. Immune modulation treatments-where is the evidence? Fertil Steril. 2017 ; 107 : 1284-93.
PubMed
P.389 掲載の参考文献
1) Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics. 24th edition. NY : McGraw-Hill Education ; 2014. p.308-9.
 
2) 大戸斉. 血液型不適合妊娠と周産期における産婦と新生児への輸血. 日本産婦人科・新生児血液学会誌. 2010 ; 19 : 1-5.
 
3) 永尾暢夫. Rh血液型. 日本輸血学会認定医師制度審議会カリキュラム委員会, 編. 改訂版日本輸血学会認定医制度指定カリキュラム. 東京 : 日本輸血学会 ; 2005. p.62-4.
 
4) 稲岡千佳子, 矢原健, 安井昌博. 当センターにおける不規則抗体陽性妊婦と出生児溶血性疾患についての考察. 日本輸血学会誌. 2013 ; 59 : 486-91.
 
5) 日本産婦人科学会・日本産婦人科医会, 編・監. 産婦人科診療ガイドライン 産科編 2017. 東京 : 日本産婦人科学会事務局 ; 2017. p.41-3.
 
6) American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.75 : Management of alloimmunization during pregnancy. Obstet Gynecol. 2006 ; 108 : 457-64.
 
7) Bowman JM. The prevention of Rh immunization. Transfus Med Rev. 1988 ; 2 : 129.
 
8) Ariga H, Ohto H, Busch MP, et al. Kinetics of fetal cellular and cell-free DNA in the maternal circulation prenatal diagnosis. Transfusion. 2001 ; 41 : 1524-30.
 
9) Mari G. Noninvasive diagnosis by doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med. 2000 ; 342 : 9-14.
 
P.394 掲載の参考文献
1) 日本産科婦人科学会, 日本産科婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2014. 2014.
 
2) 日本産科婦人科学会, 日本産科婦人科医会, 編. 産婦人科診療ガイドライン 婦人科外来編 2014. 2014.
 
3) 日本産科婦人科学会. 周産期委員会報告. 日産婦会誌. 2014 ; 62 : 1520.
 
4) Schwebke JR, Hillier SL, Sobel JD, et al. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol. 1996 ; 88 : 573-6.
 
5) Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery : A meta-analysis. Am J Obstet Gynecol. 2003 ; 189 : 139-47.
 
6) Morris M, Nicoll A, Simms I, et al. Bacterial vaginosis : a public health review. BJOG. 2001 ; 108 : 439-50.
 
7) Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. New Engl J Med. 2000 ; 342 : 1500-7.
 
8) Asakura K, Nakano M, Yamada M, et al. Effect of bidet toilet use on preterm birth and vaginal flora in pregnant women. Obstet Gynecol. 2013 ; 121 : 1187-94.
 
P.400 掲載の参考文献
1) Horne AW, Stock SJ, King AE. Innate immunity and disorders of the female reproductive tract. Reproduction. 2008 ; 135 : 739-49.
 
2) Wira CR, Grant-Tschudy KS, Crane-Godeau MA. Epithelial cells in the female reproductive tract : a central role as sentinels of immune protection. Am J Reprod Immunol. 2005 ; 53 : 65-76.
 
3) Weissenbacher ER, Wirth M, Mylonas I. General immunology of the genital tract. In : Weissenbacher ER, et al. editors. Immunology of the female genital tract. Berlin : Springer ; 2014 p.15-64.
 
4) Martyn F, McAuliffe FM, Wingfield M. The role of the cervix in fertility : is it time for a reappraisal? Hum Reprod. 2014 ; 29 : 2092-8.
 
5) Cunningham EG, Leveno KJ, Bloom SL, et al. Sexually transmitted infections. In : Cunningham EG, et al. Williams Obstetrics 24th eds. NY : McGraw-Hill ; 2014. p.1548-55.
 
6) 菅生元康. クラミジア感染症. In : 武谷雄二, 他編. 女性と感染症. 新女性医学大系. 東京 : 中山書店 ; 1999. p.116-26.
 
7) 日本性感染症学会. 性感染症 診断・治療ガイドライン 2016. 日本性感染症学会誌. 2016 ; 27 : 51-63.
 
P.406 掲載の参考文献
1) 金井雄二, 海野信也. 異常妊娠. 日産婦誌. 2008 ; 60 : N-3-8.
 
2) Cunningham F. Williams Obstetrics, 24th ed, New York : McGraw-Hill Professional ; 2014. p.872-90.
 
3) Gabbe SG. Obstetrics Normal and Problem Pregnancies, 7th ed. St. Louis : Elsevier Saunders ; 2017 p.737-69.
 
4) 鮫島浩. 胎児発育不全 (IUGR, FGR) : 適切な娩出時期. 母子保健情報. 2010 ; 61 : 46-9.
 
5) Barker DJP. Fetal and Infant Origins of Adult Disease. London : BMJ Publishing ; 1992.
 
6) Brosens I, Pijnenborg R, Vercruysse L, et al. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011 ; 204 : 193-201.
 
P.411 掲載の参考文献
1) Ohkuchi A, Hirashima C, Takahashi K, et al. Prediction and prevention of hypertensive disorders of pregnancy. Hypertens Res. 2017 ; 40 : 5-14.
 
2) Freitag N, Tirado-Gonzalez I, Barrientos G, et al. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci USA. 2013 ; 110 : 11451-6.
 
3) Hirashima C, Ohkuchi A, Nagayama S, et al. Galectin-1 as a novel risk factor for both gestational hypertension and preeclampsia, specifially its expression at a low level in the second trimester and a high level after onset. Hypertens Res. 2018 ; 41 : 45-52.
 
4) Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008 ; 14 : 855-62.
PubMed
5) Iriyama T, Wang W, Parchim NF, et al. Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015 ; 65 : 1307-15.
 
6) LaMarca B, Cornelius DC, Harmon AC, et al. Identifying immune mechanisms mediating the hypertension during preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2016 ; 311 : R1-9.
 
7) Wang W, Parchim NF, Iriyama T, et al. Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension. 2014 ; 63 : 595-606.
 
8) 「抗リン脂質抗体症候群合併妊娠の治療及び予後に関する研究」研究班, 編. 抗リン脂質抗体症候群合併妊娠の診療ガイドライン. 東京 : 南山堂 ; 2016.
 
P.417 掲載の参考文献
1) Gunn GC, Mishell DR Jr., Morton DG. Premature rupture of the fetal membranes. A review. Am J Obstet Gynecol. 1970 ; 106 : 469-83.
 
2) Taylor J, Garite TJ. Premature rupture of membranes before fetal viability. Obstet Gynecol. 1984 ; 64 : 615-20.
 
3) Mead PB. Management of the patient with premature rupture of the membranes. Clin Perinatol. 1980 ; 7 : 243-55.
 
4) Smith RP. A technic for the detection of rupture of the membranes. A review and preliminary report. Obstet Gynecol. 1976 ; 48 : 172-6.
 
5) Pasquier JC, Bujold E. A systematic review of intentional delivery in women with preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2007 ; 20 : 567-8.
 
6) Hartling L, Chari R, Friesen C, et al. A systematic review of intentional delivery in women with preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2006 ; 19 : 177-87.
 
7) Hannah ME, Ohlsson A, Farine D, et al. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group. N Engl J Med. 1996 ; 334 : 1005-10.
 
8) Seaward PG, Hannah ME, Myhr TL, et al. International Multicentre Term Prelabor Rupture of Membranes Study : evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. Am J Obstet Gynecol. 1997 ; 177 : 1024-9.
 
9) Mercer BM. Preterm premature rupture of the membranes : diagnosis and management. Clin Perinatol. 2004 ; 31 : 765-82, vi.
 
10) Gyetvai K, Hannah ME, Hodnett ED, et al. Tocolytics for preterm labor : a systematic review. Obstet Gynecol. 1999 ; 94 : 869-77.
 
11) Mercer BM. Is there a role for tocolytic therapy during conservative management of preterm premature rupture of the membranes? Clin Obstet Gynecol. 2007 ; 50 : 487-96.
 
12) Jazayeri A, Jazayeri MK, Sutkin G. Tocolysis does not improve neonatal outcome in patients with preterm rupture of membranes. Am J Perinatol. 2003 ; 20 : 189-93.
 
13) Meller CH, Izbizky G, Otano L. Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth. Arch Argent Pediatr. 2015 ; 113 : 345-51.
 
14) Bouet PE, Brun S, Madar H, et al. Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants. Sci Rep. 2015 ; 5 : 14732.
 
15) De Silva DA, Sawchuck D, von Dadelszen P, et al. Magnesium sulphate for eclampsia and fetal neuroprotection : a comparative analysis of protocols across Canadian tertiary perinatal centres. J Obstet Gynaecol Can. 2015 ; 37 : 975-87.
 
16) Committee Opinion No. 455 : Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010 ; 115 : 669-71.
 
17) Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA. 1997 ; 278 : 989-95.
 
18) Kenyon SL, Taylor DJ, Tarnow-Mordi W. ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes : the ORACLE I randomised trial. ORACLE Collaborative Group. Lancet. 2001 ; 357 : 979-88.
 
19) Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 ; 59 : 1-36.
 
20) ACOG Practice Bulletin No. 80 : premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2007 ; 109 : 1007-19.
 
21) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2017. 東京 : 日本産科婦人科学会 : 2017. p.158-62 (CQ303).
 
22) Vergani P, Ghidini A, Locatelli A, et al. Risk factors for pulmonary hypoplasia in second-trimester premature rupture of membranes. Am J Obstet Gynecol. 1994 ; 170 : 1359-64.
 
P.423 掲載の参考文献
1) Egashira M, Hirota Y, Shimizu-Hirota R, et al. F4/80+ macrophages contribute to clearance of senescent cells in the mouse postpartum uterus. Endocrinology. 2017, in press.
 
2) Hirota Y, Cha J, Yoshie M, et al. Heightened uterine mTORC1 signaling provokes preterm birth in mice. Proc Natl Acad Sci USA. 2011 ; 108 : 18073-8.
 
3) Hirota Y, Daikoku T, Tranguch S, et al. Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice. J Clin Invest. 2010 ; 120 : 803-15.
PubMed
4) Cha J, Bartos A, Egashira M, et al. Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions. J Clin Invest. 2013 ; 123 : 4063-75.
 
5) Deng W, Cha J, Yuan J, et al. p53 coordinates decidual sestrin 2/AMPK/mTORC1 signaling to govern parturition timing. J Clin Invest. 2016 ; 126 : 2941-54.
 
6) Johnston-MacAnanny EB, Hartnett J, Engmann LL, et al. Chronic endometritis is a frequent finding in women with recurrent implantation failure after in vitro fertilization. Fertil Steril. 2010 ; 93 : 437-41.
 
P.429 掲載の参考文献
1) 日本歯周病学会, 編. 歯周病と全身の健康. 東京 : 医歯薬出版 ; 2015.
 
2) Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol. 1996 ; 67 : 1103-13.
 
3) Kim AJ, Lo AJ, Pullin DA, et al. Scaling and root planing treatment for periodontitis to reduce preterm birth and low birth weight : a systematic review and meta-analysis of randomized controlled trials. J Periodontol. 2012 ; 83 : 1508-19.
 
4) Puertas A, Magan-Fernandez A, Blanc V, et al. Association of periodontitis with preterm birth and low birth weight : a comprehensive review. J Matern Fetal Neonatal Med. 2017 : 1-6.
 
5) Sgolastra F, Petrucci A, Severino M, et al. Relationship between periodontitis and pre-eclampsia : a meta-analysis. PLoS One. 2013 ; 8 : e71387.
 
6) Komine-Aizawa S, Hirohata N, Aizawa S, et al. Porphyromonas gingivalis lipopolysaccharide inhibits trophoblast invasion in the presence of nicotine. Placenta. 2015 ; 36 : 27-33.
 
7) Hirohata N, Komine-Aizawa S, Tamura M, et al. P. Gingivalis suppresses trophoblast invasion by soluble factors. J Periodontol. 2017 : 1-18. doi : 10.1902/jop.2017.170193.
 
P.434 掲載の参考文献
1) Leth RA, Moller JK, Thomasen RW, et al. Risk of selected postpartum infections after cesarean section compared with viginal birth : A five-year cofort study of 32, 468 women. Acta Obstet Gynecol Scand. 2009 ; 88 : 976-83.
 
2) Lucas DN, Robinson PN, Nel MR. Sepsis in obstetrics and the role of the anaesthetist. Int JObstet Anesth. 2012 ; 21 : 56-67.
 
3) Smaill FM, Gyte GML. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane database Syst Rev. 2014 : CD007452.
 
4) 岡本愛光, 監修. ウィリアムス産科学 原著24版. 東京 : 南江堂 ; 2015. p.819-33.
 
5) Weiss KA, Laverdoere M. Group A Streptococcus invasive infections ; A review. Can J Surg. 1997 ; 40 : 18-25.
 
6) Deutscher M, Lewis M, Zwll ER, et al, Incidence and severity of invasive Streptococcus pneumoniae, group A Streptococcus, and group B Streptococcus infections among pregnant and postpartum women, Clin Infect Dis. 2011 ; 53 : 114-23.
 
7) 原田崇, 谷口文紀, 原田省. 産褥熱. 周産期医学. 2016 ; 46 : 351-3.
 
8) 輪島丈明. β溶血性レンサ球菌感染症. 感染症診療update. 2014 ; 143 : 287-9.
 
P.438 掲載の参考文献
1) 日本産科婦人科学会・日本産婦人科医会, 編集・監修. 産婦人科診療ガイドライン 産科編 2017 ; 2017.
 
2) 井村真澄. 母乳育児. In 村田雄二. 産科合併症 第2版. 大阪 : メディカル出版 ; 2013. p.677-86.
 
3) Cunningham FG, Leveno KJ, BloomSL, et al. 23rd Williams obstetrics. McGraw-Hill Medical ; 2010. p.653-4.
 
4) Amir LH, The Academy of Breastfeeding Medicine, 著. 涌谷桐子, NPO法人日本ラクテーション・コンサルタント協会, 訳. ABM臨床プロトコル 第4号 乳腺炎 2014年改訂版. The Academy of Breastfeeding Medicine ホームページ. 2014.
 
5) K Niimi, K Usami, Y Fujita, et al. Development of immune and microbial environments is independently regulated in the mammary gland. Mucosal Immunology. 2017.
 
P.444 掲載の参考文献
1) Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome : an international collaborative study. Genet Med. 2012 ; 14 : 296-305.
 
2) Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood : a study in a clinical setting. Am J Obstet Gynecol. 2011 ; 204 : 205.e1-11.
 
3) Samura O, Sekizawa A, Suzumori N, et al. Current status of non-invasive prenatal testing in Japan. J Obstet Gynaecol Res. 2017 ; 43 : 1245-55.
 
4) Hui L, Bethune M, Weeks A, et al. Repeated failed non-invasive prenatal testing owing to low cell-free fetal DNA fraction and increased variance in a woman with severe autoimmune disease. Ultrasound Obstet Gynecol. 2014 ; 44 : 242-3.
 
5) Hui CY, Tan WC, Tan EL, et al. Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome : lessons learnt. BMJ Case Reports. 2016 ; 2016.
 
6) Chan RW, Jiang P, Peng X, et al, Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc Natl Acad Sci U S A. 2014 ; 111 : E5302-11.
 
7) Dunaeva M, Buddingh' BC, Toes RE, et al. Decreased serum cell-free DNA levels in rheumatoid arthritis. Auto Immun Highlights. 2015 ; 6 : 23-30.
 
8) Gromminger S, Erkan S, Schock U, et al. The influence of low molecular weight heparin medication on plasma DNA in pregnant women. Prenat Diagn. 2015 ; 35 : 1155-7.
 
P.448 掲載の参考文献
1) 平形道人, 訳. SECTION 2 免疫介在性障害による疾患 318 自己免疫と自己免疫疾患. In : 福井次矢, 黒川清, 監. ハリソン内科学. 第4版. 東京 : メディカル・サイエンス・インターナショナル ; 2013. p.2354.
 
2) Oktem O, Yagmur H, Bengisu H, et al. Reproductive aspects of systemic lupus erythematosus. J Reprod Immunol. 2016 ; 117 : 57-65.
 
3) Ebrahimi M, Akbari Asbagh F. The role of autoimmunity in premature ovarian failure. Iran J Reprod Med. 2015 ; 13 : 461-72.
 
4) Ayesha, Jha V, Goswami D. Premature Ovarian Failure : An Association with Autoimmune Diseases. J Clin Diagn Res. 2016 ; 10 : QC10-QC12.
 
5) Ebrahimi M1, Akbari Asbagh F, Pathogenesis and causes of premature ovarian failure : an update. Int J Fertil Steril. 2011 ; 5 : 54-65.
 
6) Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women : evaluation by using anti-Muellerian hormone. Lupus. 2011 ; 20 : 1193-7.
 
7) Ulug P, Oner G, Kasap B, et al, Evaluation of ovarian reserve tests in women with systemic lupus erythematosus. Am J Reprod Immunol. 2014 ; 72 : 85-8.
 
8) Gasparin AA, Souza L, Siebert M, et al. Assessment of anti-Mullerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus. 2016 ; 25 : 227-32.
 
9) Mayorga J, Alpizar-Rodriguez D, Prieto-Padilla J, et al. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus. 2016 ; 25 : 675-83.
 
10) Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction. 2012 ; 144 : 153-63.
PubMed
11) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013 ; 31 : 2500-10.
 
12) Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis : Advances in fertility preservation. Rheum Dis Clin N Am. 2010 ; 36 : 99-108.
 
13) Houssiau FA, Vasconcelos C, D'Cruz D. Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 ; 46 : 2121-31.
 
P.458 掲載の参考文献
1) 鈴木康夫. 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働省科学研究費補助金難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」 (鈴木班) 改訂版 ; 2017.
 
2) 鈴木康夫. 一目でわかるIBD 炎症性腸疾患を診察されている先生方への厚生労働省科学研究費補助金難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」 (鈴木班). 第2版. 2015 ; 160-3.
 
3) 上野文昭. クローン病診療ガイドライン. 難治性炎症性腸管障害に関する調査研究プロジェクト研究グループ・日本消化器病学会クローン病診療ガイドライン作成委員会・評価委員会, 2011.
 
4) 信永敏克. 消火器疾患. In : 村田雄二. 合併症妊娠. 大阪 : メディカル出版 第3版. 2012 ; 160-3.
 
5) 小林清典, 勝又伴栄, 五十嵐正広. 潰瘍性大腸炎 (UC) と妊娠についての臨床的検討. 日消誌. 1991 ; 88 : 1313-8.
 
6) Cunningham FG, Leveno KJ, BloomSL, et al. 23rd Williams Obstetrics. McGraw-Hill Medical. 2010 ; 1054-57.
 
7) Korelitz BI. Inflammatory bowel disese and pregnancy. Gastroenterol Clin North Am. 1998 ; 27 : 213-24.
 
8) Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease : a large community-based study from Northern California. Gastroenterology. 2007 ; 133 : 1106-12.
 
9) Van der Woude C.J., Ardizzone S, Bengtsun M.B, et al. The second european evidenced-based isnensus on reproductism and preqnany in inflammutory bowel disease. J of Crohns and Colitis. 2015, 107-24.
 
遠藤克哉, 高橋成一, 下平陽介, 他. 炎症性腸疾患の妊娠・分娩に関する臨床的検討. 日消誌. 2011 ; 108 : 1858-71.
 
P.463 掲載の参考文献
1) Steptoe PC, Edwards RG. Birth after the reimplantation of human embryo. Lancet. 1978 ; 312 : 366.
 
2) 鈴木雅洲, 星和彦, 星合昊. 体外受精・胚移植により受精・着床に成功した卵管性不妊症の1例. 日不妊会誌. 1983 ; 28 : 440-3.
 
3) Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983 ; 305 : 707-9.
PubMed
4) Palermo G, Joris H, Devroey P, et al. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992 ; 340 : 17-8.
PubMed
5) 平成28年度倫理委員会登録・調査小委員会報告 (2015年分の体外受精・胚移植等の臨床実施成績および2017年7月における登録施設名). 日産婦誌. 2017 ; 69 : 1841-915.
 
6) Lutjen P, Trounson A, Leeton J, et al. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984 ; 307 : 174-5.
 
7) European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2013 : results generated from European registers by ESHRE. Hum Reprod. 2017 ; 32 : 1957-73.
 
8) National Center for Chronic Disease Prevention and Health Promotion of the Centers for Disease Control and Prevention. 2015 Assisted Reproductive Technology National Summary Report. 2017.
 
9) Storgaard M, Loft A, Bergh C, et al. Obstetric and neonatal complications in pregnancies conceived after oocyte donation : a systematic review and meta-analysis. BJOG. 2017 ; 124 : 561-72.
PubMed
10) Gundogan F, Bianchi DW, Scherjon SA, et al. Placental pathology in egg donor pregnancies. Fertil Steril. 2010 ; 93 : 397-404.
 
11) van der Hoorn ML, Lashley EE, Bianchi DW, et al. Clinical and immunologic aspects of egg donation pregnancies : a systematic review. Hum Reprod Update. 2010 ; 16 : 704-12.
 
12) Lashley LE, Haasnoot GW, Spruyt-Gerritse M, et al. Selective advantage of HLA matching in successful uncomplicated oocyte donation pregnancies. J Reprod Immunol. 2015 ; 112 : 29-33.
 
P.471 掲載の参考文献
1) 宮崎泰司. 血液学のなかの再生医療. 日産婦新生児血会誌. 2017 ; 26 : 9-15.
 
2) 中林正雄. 臍帯血バンク. 周産期医学. 2011 ; 41 (増刊号) : 441-2.
 
3) 原宏. 臍帯血移植. 東京 : 新興医学出版社 ; 2006. p.30-9.
 
4) 国立がん研究センター. がん情報サービス. 造血幹細胞移植の種類. <http://ganjoho.jp/public/dia_tre/treatment/HSCI/type.html>
 
5) 浅野茂隆, 池田康夫, 内山卓, 監. 三輪血液病学. 東京 : 文光堂 ; 2006. p.833-4.
 
6) 神田善伸, 編. みんなに役立つ造血幹細胞移植の基礎と臨床 上巻. 大阪 : 医薬ジャーナル. 2008. p.255-63.
 
7) 国立がん研究センター. がん情報サービス. 造血幹細胞移植の副作用. <http://ganjoho.jp/public/dia_tre/treatment/HSCI/SE_GVHD.html#prg7_1>
 
8) 鈴木俊治. 臍帯血バンク. 周産期医学. 2016 ; 46 (増刊号) : 474-5.
 
9) 非典型溶血性尿毒症症候群基準改定委員会. 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日腎会誌. 2016 ; 58 : 62-75.
 
10) 日本造血細胞移植データセンター. 日本における造血幹細胞移植の実績 2016年度. <http://www.jdchct.or.jp/data/slide/2016/transplants_2016_JDCHCT_20170324.pdf>
 
11) Cotten CM, Murtha AP, Goldberg RN, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr 2014 ; 164 : 973-9.
 
12) Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation : public or private? (review) Bone Marrow Transplantation. 2015 ; 50 : 1271-478.
 
P.482 掲載の参考文献
1) 砂川富正, 荒川創一. 厚生労働科学研究費補助金新興・再興感染症及び予防接種政策推進研究事業. 「性感染症に関する特定感染症予防指針に基づく対策の推進に関する研究」, 平成28年度報告.
 
2) Johnson BA, Poses RM, Fortner CA. Derivation and validation of a clinical diagnostic model for chlamydial cervical infection in university women. JAMA. 1990 ; 264 : 3161-5.
PubMed
3) Dean D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis. 2000 ; 182 : 909-16.
PubMed
4) Westrom L, Joesoef R, Reynolds G. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992 ; 19 : 185-92.
 
5) Broeze KA, Opmeer BC, Coppus SF. Chlamydia antibody testing and diagnosing tubal pathology in subfertile women : an individual patient data meta-analysis. Hum Reprod Update. 2011 ; 17 : 301-10.
 
6) Tiitinen A, Surcel HM, Halttunen M. Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility. Hum Reprod. 2006 ; 21 : 1533-8.
 
P.487 掲載の参考文献
1) He J, Liu M, Ye Z, et al. Insights into thepathogenesis of Mycoplasma pneumoniae (Review). Mol Med Rep. 2016 14 : 4030-6. Epub 2016 Sep 23. Review.
 
2) Baheerathan A, Ross Russell A, Bremner F. A rare case of bilateral optic neuritis and Guillain-Barre syndrome post Mycoplasma pneumoniae Infection. Neuroophthalmology. 2016 41 : 41-7.
 
3) Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, et al. Mycoplasma pneumoniae triggering the Guillain-Barre syndrome : A case-control study. Ann Neurol. 2016 80 : 566-80.
 
4) Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease : a meta-analysis. Clin Infect Dis. 2015 ; 61 : 418-26.
 
P.493 掲載の参考文献
1) Sherad MC. The recovery of pleuropneumonia-like organisms from Negro men with and without nongonococcal urethritis. Am J Syph Gonorrhea Vener Dis. 1954 ; 38 : 113-24.
 
2) Ford DK. Culture of human genital "T-STRAIN" pleuropneumonia-like organisms. J Bacteriol. 1962 ; 84 : 1028-34.
 
3) Qing L, Song QX, Feng JL, et al. Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Ureaplasma urealyticum infections using a novel isothermal simultaneous RNA amplification testing method in infertile males. Ann Clin Microbiol Antimicrob. 2017 ; 16 : 45.
 
4) Kapatais-Zoumbos K, Chandler DK, Barile MF. Survey of immunoglobulin A protease activity among selected species of Ureaplasma and Mycoplasma : specificity for host immunoglobulin A. Infect Immun. 1985 ; 47 : 704-9.
 
5) Lee SE, Romero R, Kim EC, et al. A high Nugent score but not a positive culture for genital mycoplasmas is a risk factor for spontaneous preterm birth. J Matern Fetal Neonatal Med. 2009 ; 22 : 212-7.
 
6) Harada K, Tanaka H, Komori S, et al. Vaginal infection with Ureaplasma urealyticum accounts for preterm delivery via induction of inflammatory responses. Microbiol Immunol. 2008 ; 52 : 297-304.
 
P.497 掲載の参考文献
1) Mao C, Hughes JP, Koutsky LA, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol. 2003 ; 188 : 677-84.
 
2) Park IU, Introcaso C, Dunne EF. Human Papillomavirus and genital warts : A review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015 ; 61 8 : S849-55. doi : 10.1093/cid/civ813
 
3) Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 ; 64 : 1-137.
PubMed
4) Zur Hausen H. Papillomavirus and cancer. From basic studies to clinical application. Nature Review. 2002 ; 5 : 342-50.
 
5) Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012 ; 25 : 215-22. doi : 10.1128/CMR.05028-11.
 
6) Oliphant J, Stewart J, Ward D, et al. Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. N Z Med J. 2017 ; 130 : 9-16.
 
P.503 掲載の参考文献
1) Yamamoto M, Okuyama M, Ma JS, et al. A cluster of interferon-γ-inducible p65 GTPases plays a critical role in host defense against Toxoplasma gondii. Immunity. 2012 ; 37 : 302-13.
 
2) 小島俊行, 他. トキソプラズマ. 産科と婦人科. 2008 ; 75 : 1662-72.
 
3) Wallon M, Franck J, Thulliez P, et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet Gynecol. 2010 ; 115 : 727-33.
 
4) Hohlfeld P, Daffos F, Costa JM, et al. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med. 1994 ; 331 : 695-9.
PubMed
5) Berrebi A, Assouline C, Bessieres MH, et al. Long-term outcome of children with congenital toxoplasmosis. Am J Obstet Gynecol. 2010 ; 203 : 552.e1-6.
 
P.508 掲載の参考文献
1) 厚生労働省ホームページ. 風しんについて. <http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/rubella/>
 
2) 谷垣伸治, 金沢誠司, 松島幸生, 他. 風疹 特集 妊娠と感染症-外来で聞かれてどう説明する? 産科と婦人科. 2016 ; 83 : 1004-9.
 
3) 日本産婦人科医会ホームページ. <http://www.jaog.or.jp/rubella/>
 
4) 診療対応の概略フロー図. <http://idsc.nih.go.jp/iasr/32/379/graph/df37951.gif>
 
5) 厚生労働科学研究費補助金新型インフルエンザ等 新興・再興感染症研究事業. <http://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000026976.pdf>
 
6) "風疹ゼロ" プロジェクト. <http://www.jaog.or.jp/all/103_161109.pdf>
 
P.514 掲載の参考文献
1) 石橋麻奈美, 森内浩幸. サイトメガロウイルス抗体保有率の変遷～妊娠・周産期管理の方向性～. 日本産婦人科・新生児血液学会誌. 2017 ; 26 : 29-34.
 
2) Toriyabe K, Morikawa F, Ikeda T, et al. Anti-cytomegalovirus immunoglobulin M titer for congenital infection in first-trimester pregnancy with primary infection : a multicenter prospective cohort study. J Perinatol. 2017 doi : 10.1038/jp.2017.133 [In press]
 
3) Fujii T, Oka A, Inoue N, et al ; Japanese Congential Cytomegalovirus Study Group. Newborn congential cytomegalovirus screening based on clinical manifestations and evaluation of DNA-based assays for in vitro diagnostics. Pediatr Infect Dis J. 2017 ; 36 : 942-46.
 
4) Fujii T, Oka A, Inoue N, et al. Newborn congenital cytomegalovirus screening based on clinical manifestations and evaluation of DNA-based assays for in vitro diagnostics. Pediatr Infect Dis J. 2017 doi : 10.1097/INF.0000000000001630. [Epub ahead of print].
 
5) 北村亜紗, 鳥谷部邦明, 池田智明, 他. 妊娠中のサイトメガロウイルス (CMV) 肝炎および慢性胆嚢炎の一例. 東海産科婦人科学会雑誌. 2017 ; 53 : 183-9.
 
6) 日本産科婦人科学会/日本産婦人科医会. 産婦人科診療ガイドライン 産科編 2017. 東京 : 日本産科婦人科学会 ; 2017.
 
P.518 掲載の参考文献
1) Okada K, Kamiyama M, Inomata M, et al. E antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976 ; 294 : 746-49.
 
2) 日本小児科学会. B 型肝炎ウイルス母子感染予防のための新しい指針. 2013. <https://www.jpeds.or.jp/uploads/files/HBV20131218.pdf>
 
3) Dunkelberg JC, Berkley EM, Thiel KW, et al. Hepatitis B and C in pregnancy : a review and recommendations for care. J Perinatol. 2014 ; 34 : 882-91.
 
4) 厚生労働科学研究補助金「肝炎等克服緊急対策研究事業」C型肝炎ウイルス等の母子感染防止に関する研究班 : C型肝炎ウイルス (HCV) キャリア妊婦とその出生児の管理指導指針 (平成16年12月). 日本小児科学会雑誌. 2005 ; 109 : 78-9.
 
5) 厚生労働科研「C型肝炎ウイルス等の母子感染防止に関する研究 (主任研究者 : 大戸斉) 」平成17年度総括分担研究報告書. 2006年3月 (III).
 
P.524 掲載の参考文献
1) ACOG : Management of Herpes in pregnancy : ACOG Practice Bulletin, Clinical Management Guidolines for Obstetrician-Gynecologists. 2007 ; 82 : 1489-98.
 
2) Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003 ; 289 : 203-9.
 
3) 森島恒雄, 川名尚, 平川宗弘. 新生児ヘルペスの全國調査. 日本小児科学会誌. 1989 ; 93 : 1990-5.
 
4) Ito Y, Kimura H, Torii Y, et al. Japanese Society for Pediatric Infectious Diseases. Risk factors for poor outcome in congenital cytomegalovirus infection and neonatal herpes on the basis of a nationwide survey in Japan. Pediatr Int. 2013 ; 55 : 566-71.
 
5) Kawada J, Kimura H, Ito Y, et al. Evaluation of systemic inflammatory responses in neonates with herpes simplex virus infection. J Infect Dis. 2004 ; 190 : 494-8.
 
6) Nagamori T, Koyano S, Asai Y, et al. Sequential changes in pathophysiology of systemic inflammatory response in a disseminated neonatal herpes simplex virus (HSV) infection. J Clin Virol. 2012 ; 53 : 265-7.
 
7) Pinninti SG, Angera R, Feja KN. Neonatal herpes disease following maternal antenatal antiviral supprssive therapy : a multicenter case series. J Pediatr. 2012 ; 161 : 134-8.
 
8) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2017. 2017.
 
9) 木村宏, 葛島清隆, 森島恒雄, 他. 新生児ヘルペス全身型に伴う肝機能異常の早期診断における重要性について. 日児誌. 1991 ; 95 : 955-9.
 
10) Kimberlin DW, Lin CY, Jacobs RF, et al ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001 ; 108 : 230-8.
 
P.530 掲載の参考文献
1) Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy : prospective evaluation of 1018 cases. Prenat Diagn. 2004 ; 24 : 513-8.
 
2) Rodis JF, Borgida AF, Wilson M, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops : a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol. 1998 ; 179 : 985-8.
 
3) Cosmi E, Mari G, Delle Chiaie L, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol. 2002 ; 187 : 1290-3.
 
4) 山田秀人 (研究代表者). 先天性サイトメガロウイルス感染症対策のための妊婦教育の効果の検討, 妊婦・新生児スクリーニング体制の構築及び感染新生児の発症リスク同定に関する研究. 厚生労働科学研究費補助金 (成育疾患克服等次世代育成基盤研究事業) 平成23～24年度総合研究報告書. 2013 ; p.1-201. <http://mhlw-grants.niph.go.jp/niph/search/NIST00.do> よりダウンロード可能)
 
5) Yamada H, Tairaku S, Morioka I, et al. Nationwide survey of mother-to-child infections in Japan. J Infect Chemother. 2015 ; 21 : 161-4.
 
P.535 掲載の参考文献
1) Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008 ; 14 : 1232-9.
PubMed
2) Driggers RW, Ho CY, Korhonen EM, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med. 2016 ; 374 : 2142-51
 
3) Lustig Y, Mendelson E, Paran N, et al. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. Euro Surveill. 2016 ; 21.
 
4) Turmel JM, Abgueguen P, Hubert B, et al. Late sexual transmission of Zika virus related to persistence in the semen. Lancet. 2016 ; 387 : 2501.
 
5) Arsuaga M, Bujalance SG, Diaz-Menendez M, et al. Probable sexual transmission of Zika virus from a vasectomised man. Lancet Infect Dis. 2016 ; 16 : 1107.
 
6) Jimenez A, Shaz BH, Bloch EM. Zika virus and the blood supply : What do we know? Transfus Med Rev. 2017 ; 31 : 1-10.
 
7) Dupont-Rouzeyrol M, Biron A, O'Connor O, et al. Infectious Zika viral particles in breastmilk. Lancet. 2016 ; 387 : 1051.
 
8) Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009 ; 360 : 2536-43.
PubMed
9) Tappe D, Perez-Giron JV, Zammarchi L, et al. Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase. Med Microbiol Immunol. 2016 ; 205 : 269-73
 
10) Cauchemez S, Besnard M, Bompard P, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15 : a retrospective study. Lancet. 2016 ; m387 : 2125-32.
 
11) Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, et al. Zika and the risk of microcephaly. N Engl J Med. 2016 ; 375 : 1-4.
PubMed
12) Cavalheiro S, Lopez A, Serra S, et al. Microcephaly and Zika virus : neonatal neuroradiological aspects. Childs Nerv Syst. 2016 ; 32 : 1057-60.
 
13) de Fatima Vasco Aragao M, van der Linden V, Brainer-Lima AM, et al. Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly : retrospective case series study. BMJ. 2016 ; 353 : i1901.
 
14) Bayless NL, Greenberg RS, Swigut T, et al. Zika virus infection induces cranial neural crest cells to produce cytokines at levels detrimental for neurogenesis. Cell Host Microbe. 2016 ; 20 : 423-8.
 
15) Liang Q, Luo Z, Zeng J, et al. Zika virus NS4A and NS4B proteins deregulate Akt-mTOR signaling in human fetal neural stem cells to inhibit neurogenesis and induce autophagy. Cell Stem Cell. 2016 ; 19 : 663-71.
 
16) Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia : a case-control study. Lancet. 2016 ; 387 : 1531-9.
PubMed
17) Parra B, Lizarazo J, Jimenez-Arango JA, et al.. Guillain-Barre syndrome associated with Zika virus infection in Colombia. N Engl J Med. 2016 ; 375 : 1513-23.
 
18) Muller JA, Harms M, Schubert A, et al. Inactivation and environmental stability of Zika virus. Emerg Infect Dis. 2016 ; 22 : 1685-7.
 
19) 国立感染症研究所. 蚊媒介感染症ガイドライン 第4版. 2016.
 
20) Brasil P, Calvet GA, Siqueira AM, et al. Zika virus outbreak in Rio de Janeiro, Brazil : clinical characterization, epidemiological and virological aspects. PLoS Negl Trop Dis. 2016 ; 10 : e0004636.
 
P.542 掲載の参考文献
1) Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 ; 355 : 2283-96.
 
2) Cohen MS, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 ; 365 : 493-505.
PubMed
3) Bailey JL, Molino ST, Vega AD, et al. A review of HIV pre-exposure prophylaxis : the female perspective. Infect Dis Ther. 2017 Jun 9. doi : 10.1007/s40121-017-0159-9. [Epub ahead of print]
 
4) Kudoh A, Miyakawa K, Hayakawa S, et al. H11/HSPB8 restricts HIV-2 Vpx to restore the anti-viral activity of SAMHD1. Front Microbiol. 2016 ; 7 : 883.
 
5) Quillay H, El Costa H, Duriez M, et al. NK cells control HIV-1 infection of macrophages through soluble factors and cellular contacts in the human decidua. Retrovirology. 2016 ; 13 : 39.
 
6) 厚生労働科学研究補助金エイズ対策事業 平成25年度. HIV母子感染予防対策マニュアル 第7版. <http://api-net.jfap.or.jp/library/guideLine/boshi/images/H25_manual.pdf>
 
P.550 掲載の参考文献
1) 厚生労働省科学研究費補助金・新型インフルエンザ等新興・再興感染症研究事業「本邦におけるHTLV-1感染及び関連疾患の実態調査と総合対策」 (研究代表者 : 山口一成). 平成21年度総括研究報告書.
 
2) 厚生労働科学研究費補助金・特別研究事業「ヒトT細胞白血病ウイルス-1型 (HTLV-1) 母子感染予防のための保健指導に関する標準化に関する研究」 (研究代表者 : 森内浩幸). 平成22年度研究報告書 (保健指導マニュアル).
 
3) 厚生労働省科学研究費補助金・特別研究事業「HTLV-1の母子感染予防に関する研究」 (研究代表者 : 斎藤滋). 平成21年度総括・分担報告書. (医師向け手引き)
 
4) Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers : a nationwide prospective study in Japan. Blood. 2010 ; 116 : 1211-9.
 
5) 厚生労働科学研究補助金 (成育疾患克服等次世代育成基盤研究事業) 「HTLV-1母子感染予防に関する研究 : HTLV-1抗体陽性妊婦からの出生児のコホート研究」 (研究代表者 : 板橋家頭夫) HTLV-1母子感染予防対策マニュアル. 2016. <http://htlv-1mc.org/news/#post-id-3074>
 
6) 厚生労働科学研究補助金 (成育疾患克服等次世代育成基盤研究事業) 「HTLV-1母子感染予防に関する研究 : HTLV-1抗体陽性妊婦からの出生児のコホート研究」 (研究代表者 : 板橋家頭夫). 平成24年度総括研究報告書.
 
7) Moriuchi H, Masuzaki H, Doi H, et al. Mother-to-child transmission of human T cell lymphotropic virus type 1. Pediatr Infect Dis J. 2013 ; 32 : 175-7.
 
P.561 掲載の参考文献
1) zur Hausen H. Papillomavirus and cancer : from basic studies to clinical application. Nat Rev Cancer. 2002 ; 2 : 342-50.
 
2) Bosch FX, de Sanjose S, et al. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003 ; 31 : 3-13.
 
3) The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. Geneva. 16-18 February, 1999.
 
4) Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010 ; 118 : 450-4.
 
5) Shah KV. A case for immunization of HPV6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis. 2014 ; 209 : 1307-9.
 
6) Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross protection after a human papillomavirus vaccination programme in Australia : a repeat cross-sectional study. Lancet Infect Dis. 2014 ; 14 : 958-66.
 
7) Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014 ; 110 : 2804-11.
 
8) Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013 ; 208 : 385-93.
 
9) Brotherton J, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia : an ecological study. Lancet. 2011 ; 377 : 2085-92.
 
10) 国立がん研究センターがん対策情報センター. がん対策推進基本計画中間評価報告書 (平成27年6月1日).
 
11) 第15回厚生科学審議会予防接種・ワクチン分科会副反応検討部会 (平成27年9月17日開催) 資料4-1.
 
12) European Medicine Agency (EMA), Pharmacovigilance Risk Assessment Com mittee (PRAC). Review concludes evidence does not support that HPV vaccines cause CRPS or POTS, 5th November, 2015.
 
13) 第23回厚生科学審議会予防接種・ワクチン分科会副反応検討部会. 全国疫学調査〔子宮頸がんワクチンの有効性と安全性の評価に関する疫学研究 (祖父江班) 〕. (2016年12月26日開催) 資料
 
14) 公益社団法人 日本医師会・日本医学会. HPVワクチン接種後に生じた症状に対する診療の手引き. 2015.
 
P.567 掲載の参考文献
1) Nonaka H, Saga Y, Fujiwara H, et al. Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion. Int J Oncol. 2011 ; 38 : 113-20.
 
2) Wang D, Saga Y, Fujiwara H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012 ; 40 : 929-34.
 
3) Sato N, Saga Y, Fujiwara H, et al. Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation. Oncol Rep. 2012 ; 28 : 1574-8.
 
4) Wang D, Saga Y, Fujiwara H, et al. The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway. Int J Oncol. 2016 ; 48 : 2303-9.
 
P.572 掲載の参考文献
1) Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 ; 363 : 711-23.
PubMed
2) Calabro L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma : an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 ; 3 : 301-9.
 
3) Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer : a multicentre, phase 1b study. Lancet Oncol. 2016 ; 17 : 299-308.
 
P.577 掲載の参考文献
1) van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 ; 254 : 1643-7.
 
2) Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy : moving beyond current vaccines. Nat Med. 2004 ; 10 : 909-15.
 
3) Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 ; 368 : 1509-18.
PubMed
4) Kandalaft LE, Powell DJ Jr, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med. 2012 ; 10 : 157.
 
5) Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015 ; 75 : 22-30.
 
P.586 掲載の参考文献
1) Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008 ; 26 : 677-704.
 
2) Okazaki T, Honjo T. PD-1 and PD-1 ligands : from discovery to clinical application. Int Immunol. 2007 ; 19 : 813-24.
 
3) Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007 ; 104 : 3360-5.
 
4) Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment : perspectives and issues. Int J Clin Oncol. 2016 ; 21 : 462-73. Review.
 
5) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.
PubMed
6) Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapy targeting PD-1 signaling pathway. J Biomed Sci. 2017 ; 24 : 26. Review.
 
7) Hamanishi J, Mandai M, Ikeda T, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab : BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015 ; 33 : 4015-22.
 
8) Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. Int Immunol. 2016 ; 28 : 339-48.
PubMed
9) Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 ; 202 : 231-7.
 
P.596 掲載の参考文献
1) 剣持敬, 福嶌教偉, 肥沼幸, 他. 臓器移植後妊娠・出産ガイドライン. 移植. 2014 ; 49 : 393-401.
 
2) 日本腎臓学会学術委員会腎疾患患者の妊娠・診察の手引き改訂委員会, 編. 腎疾患患者の妊娠診療ガイドライン 2017. 東京 : 診断と治療社. 2017.
 
3) Deshpande NA, James NT, Kucirka LM, et al. Pregnancy outcomes in kidney transplant recipients : a systematic review and meta-analysis. Am J Transplant. 2011 ; 11 : 2388-404.
 
4) Toma H, Tanabe K, Tokumoto T, et al. Pregnancy in women receiving renal dialysis or transplantation in Japan : a nationwide survey. Nephrol Dial Transplant. 1999 ; 14 : 1511-6.
 
5) Josephson MA, McKay DB. Women and transplantation : fertility, sexuality, pregnancy, contraception. Adv Chronic Kidney Dis. 2013 ; 20 : 433-40.
 
6) Kubo S, Uemoto S, Furukawa H, et al. Pregnancy outcomes after living donor liver transplantation : results from a Japanese survey. Liver Transpl. 2014 ; 20 : 576-83.
 
7) Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR) : outcomes of pregnancy after transplantation. Clin Transpl. 2009 ; 103-22.
 
8) 日本妊娠高血圧学会, 編. 妊娠高血圧症候群の診療指針2015-Best Practice Guide-東京 : メジカルビュー社. 2015.
 
9) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2014. 2014.
 
P.602 掲載の参考文献
1) Fageeh W, Raffa H, Jabbad H, et al. Transplantation of the human uterus. Int J Gynaecol Obstet. 2004 ; 76 : 245-251.
 
2) Erman Akar M, Ozkan O, Aydinuraz B, et al. Clinical pregnancy after uterus transplantation. Fertil Steril. 2013 ; 100 : 1358-63.
 
3) Brannstrom M, Johannesson L, Dahm-Kahler P, et al. First clinical uterus transplantation trial : a six-month report. Fertil Steril. 2014 ; 101 : 1228-36.
 
4) Brannstrom M, Johannesson L, Bokstrom H, et al. Livebirth after uterus transplantation. Lancet. 2015 ; 385 : 607-16.
PubMed
5) Johannesson L, Kvarnstrom N, Molne J, et al. Uterus transplantation trial : 1-year outcome. Fertil Steril. 2015 ; 103 : 199-204.
PubMed
6) Molne J, Broecker V, Ekberg J, et al. Monitoring of human uterus transplantation with cervical biopsies : A provisional scoring system for rejection. Am J Transplant. 2017 ; 17 : 1628-36.
 
P.609 掲載の参考文献
1) Levidiotis V, Chang S, McDonald S. Pregnany and maternal outcomes among kidney transplant recipients. J Am Soc Nephrol. 2009 ; 20 : 2433-40.
 
2) Mckay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation : report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J transplant. 2005 ; 5 : 1592-99.
 
3) 松田義雄. 腎疾患合併妊娠. 産科と婦人科. 2005 ; 72 : 1505-13.
 
4) Armenti VT, Daller JA, Constantinescu S, et al. Report from the National Transplantation Pregnancy Registry : outcomes of pregnancy after transplantation. Clin Transpl. 2006 ; 57-70.
 
5) 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2014. 2014.
 
6) Coscia LA, Constantinescu S, Moritz MJ, et al. Report from National Transplantation Pregnancy Registry (NTPR) : outcomes of pregnancy after transplantation. Clin Transpl. 2009 ; 103-22.
 
7) Sibanda N, Briggs JD, Davison JM, et al. Pregnancy after organ transplantation : a report from the UK Transplant pregnancy registry. Transplantation. 2007 ; 83 : 1301-7.
 
8) 剣持敬, 福嶌教偉, 肥沼幸, 他. 臓器移植後妊娠・出産ガイドライン. 移植. 2014 ; 49 : 393-401.
 
9) Williams D, Davison J. Renal disease. Maternal Fetal Medicine 6th ed. Philadelphia : Saunders ; 2009. p.905-25.
 
10) 丹波優莉, 加藤紀子, 伊藤聡, 他. 当院における腎移植後妊娠60例の検討. 日本周産期・新生児医学会雑誌. 2015 ; 51 : 1142-9.
 
P.616 掲載の参考文献
1) Talwar GP, Singh O, Pal R, et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci U S A. 1994 ; 91 : 8532-6.
 
2) Murty GS, Rani CS, Moudgal NR, et al. Effect of passive immunization with specific antiserum to FSH on the spermatogenic process and fertility of adult male bonnet monkeys (Macaca radiata). Reprod Fertil Suppl. 1979 ; 26 : 147-63.
 
3) Hannesdottir SG, Han X, Lund T, et al. Changes in the reproductive system of male mice immunized with a GnRH-analogue conjugated to mycobacterial hsp70. Reproduction. 2004 ; 128 : 365-71.
 
4) Isojima S, Kameda K, Tsuji Y, et al. Establishment and characterization of a human hybridoma secreting monoclonal antibody with high titers of sperm immobilizing and agglutinating activities against human seminal plasma. J Reprod Immunol. 1987 ; 10 : 67-78.
PubMed
5) Hasegawa A, Shigeta M, Shibahara H. Sperm immobilizing antibody and its target antigen. In : Krause WKH, et al. Editors. Immune Infertility. Springer International Publishing ; 2017. p.173-84.
 
6) Naz RK, Saver AE. Immunocontraception for Animals : Current Status and Future Perspective. Am J Reprod Immunol. 2016 ; 75 : 426-39.
 
P.623 掲載の参考文献
1) World Health Organization. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections : Overview and Estimates (World Health Organization, Geneva, 2001).
 
2) den Hartog JE, Morre SA, Land JA. Chlamydia trachomatis-associated tubal factor subfertility : Immunogenetic aspects and serological screening. Hum Reprod Update. 2006 ; 12 : 719-30.
PubMed
3) Peipert JF. Cinical practice. Genital chlamydial infections. N Engl J Med. 2003 ; 349 : 2424-30.
 
4) 熊本悦明, 塚本泰司, 利部輝雄. 日本における性感染症 (STD) サーベイランス 2001年度調査報告. 日本性感染症学会雑誌. 2002 ; 13 : 147-67.
 
5) Hu VH, Holland MJ, Burton MJ. Trachoma : protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl Trop Dis. 2013 ; 7 : e2020.
 
6) WHO. Sexually transmitted infections (STIs) ; 2015.
 
7) Ault KA, Statland BD, King MM, et al. Antibodies to the chlamydial 60 kilodalton heat shock protein in women with tubal factor infertility. Infect Dis Obstet Gynecol. 1998 ; 6 : 163-7.
 
8) Ostaszewska-Puchalska I, Wilkowska-Trojniel M, Zdrodowska-Stefanow B, et al. Chlamydia trachomatis infections in women with adverse pregnancy outcome. Med Wieku Rozwoj. 2005 ; 9 : 49-56.
PubMed
9) Spandorfer SD, Neuer A, LaVerda D, et al. Previously undetected Chlamydia trachomatis infection, immunity to heat shock proteins and tubal occlusion in women undergoing in-vitro fertilization. Hum Reprod. 1999 ; 14 : 60-4.
PubMed
10) Neuer A, Mele C, Liu HC, et al. Monoclonal antibodies to mammalian heat shock proteins impair mouse embryo development in vitro. Hum Reprod. 1998 ; 13 : 987-90.
PubMed
11) LaVerda D, Kalayoglu MV, Byrne G. Chlamydial heat shock proteins and disease pathology : new paradigms for old problems? Infect Dis Obstet Gynecol. 1999 ; 7 : 64-71.
PubMed
12) 竹村由里, 西井修. クラミジア感染症. 産婦人科の実際. 2014 ; 62 : 471-7.
 
13) LaVerda D, Kalayoglu MV, Byrne G. Chlamydial heat shock proteins and disease pathology : new paradigms for old problems? Infect Dis Obstet Gynecol. 1999 ; 7 : 64-71.
PubMed
14) Tiitinen A, Surcel HM, Halttunen M, et al. Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility. Hum Reprod. 2006 ; 21 : 1533-8.
PubMed
15) 日本性感染症学会. 性器クラミジア感染症. 性感染症診断・治療ガイドライン 2011. 日本性感染症学会誌. 2011 ; 22 : 60-4.
 
16) Grayston JT, Woolridge RL, Wang S. Trachoma vaccine studies on Taiwan. Ann N Y Acad Sci. 1962 ; 98 : 352-67.
 
17) Nichols RL, Bell SD Jr, Haddad NA, et al. Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent rachoma vaccine at three dosage levels. Am J Trop Med Hyg. 1969 ; 18 : 723-30.
 
18) Rockey DD, Wang J, Lei L, et al. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines. 2009 ; 8 : 1365-77.
PubMed
19) Schautteet K, De Clercq E, Vanrompay D. Chlamydia trachomatis vaccine research through the years. Infect Dis Obstet Gynecol. 2011 ; 2011 : 963513.
PubMed
20) Hiroi T, Goto H, Someya K, et al. HIV mucosal vaccine : nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol. 2001 ; 167 : 5862-7.
PubMed
21) Stary G, Olive A, Radovic-Moreno AF, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cell. Science. 2015 ; 348 : aaa8205.
 
22) 松田静治. 性感染症の細菌の動向. 臨床婦人科産科. 2009 ; 63 : 110-5.
 
P.629 掲載の参考文献
1) Boscato LM, Stuart MC. Heterophilic antibodies : a problem for all immunoassays. Clin Chem. 1988 ; 34 : 27-33.
 
2) Bolstad N, Warren DJ, Nustad K. Heterophilic interference in immunometric assays. Best Pract Clin Endocrinol Metab. 2013 ; 27 : 647-61.
 
3) Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999 ; 45 : 942-56.
 
4) Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet. 2000 ; 355 : 712-5.
 
P.634 掲載の参考文献
1) Nigam M, Aschebrook-Kilfoy B, Shikanov S, et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2014.
 
2) Jacobs LA, Vaughn DJ. Hypogonadism and infertility in testicular cancer survivors. J Natl Compr Canc Netw. 2012 ; 10 : 558-63.
 
3) Hanna NH, Einhorn LH. Testicular cancer discoveries and updates. N Engl J Med. 2014 ; 371 : 2005-16.
 
4) 日本泌尿器科学会, 編. 精巣腫瘍診療ガイドライン 2009年版. 東京 : 金原出版 ; 2009.
 
5) Williams DH 4th, Karpman E, Sander JC, et al. Pretreatment semen parameters in men with cancer. J Urol. 2009 ; 181 : 736-40.
 
6) Fraietta R, Spaine DM, Bertolla RP, et al. Individual and seminal characteristics of patients with testicular germ cell tumors. Fertil Steril. 2010 ; 94 : 2107-12.
 
7) Fertile Hope. Personal accounts of cancer and infertility. Cancer Treat Res. 2007 ; 138 : 243-55.
 
8) Shin T, Kobayashi T, Shimomura Y, et al. Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy. Int J Clin Oncol. 2016 ; 21 : 1167-71.
PubMed
9) Shalet SM. Effect of irradiation treatment on gonadal function in men treated for germ cell cancer. Eur Urol. 1993 ; 23 : 148-51.
 
10) Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011 ; 60 : 516-26.
 
11) Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer : a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005 ; 97 : 1056-66.
 
12) Suzuki K, Shin T, Shimomura Y, et al. Spermatogenesis in tumor-bearing testes in germ cell testicular cancer patients. Hum Reprod. 2015 ; 30 : 2853-8.
PubMed
P.638 掲載の参考文献
1) Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014 ; 89 : 306-09.
 
2) Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008 ; 22 : 235-45.
PubMed
P.639 掲載の参考文献
1) Bermas BL, Smith NA. Pregnancy in women with systemic lupus erythematosus. In : UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed on June 14, 2017).
 
P.644 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295-306.
 
2) 不育症の検査・診断, (2) 抗リン脂質抗体. In : 日本生殖医学会, 編. 生殖医療の必修知識. 東京 : 日本生殖医学会 ; 2017. p.415-21.
 
3) Matsuura E, Igarashi Y, Yasuda T, et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994 ; 179 : 457-62.
 
4) Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992 ; 148 : 3885-91.
 
5) Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000 ; 43 : 1982-93.
 
6) Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 1995 ; 86 : 3083-9.
PubMed
7) Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants : an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995 ; 74 : 1185-90.
 
8) 「抗リン脂質抗体症候群合併妊娠の治療及び予後に関する研究」研究班, 編. 抗リン脂質抗体症候群合併妊娠の診療ガイドライン. 東京 : 南山堂 ; 2016.
 
9) Levy RA, Dos Santos FC, de Jesus GR, et al. Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy : Diagnostic Concepts. Front Immunol. 2015 ; 6 : 205.
 
P.647 掲載の参考文献
1) Moratto D, Gulino AV, Fontana S, et al. Combined decrease of defined B and T cell subsets in a group of common variable immunodeficiency patients. Clin Immunol. 2006 ; 121 : 203-14.
 
2) Romberg N, Chamberlain N, Saadoun D. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest. 2013 ; 123 : 4283-93.
 
3) Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012 ; 119 : 1650-7.
 
4) Liese JG, Wintergerst U, Tympner KD, et al. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child. 1992 ; 146 : 335-9.
 
P.651 掲載の参考文献
1) 齋藤滋, 丸山哲夫, 田中忠夫, 他. 血栓性素因のある不育症に対するヘパリンカルシウム自己皮下注射の安全性についての検討. 日本産婦人科・新生児血液学会誌. 2011 ; 21 : 9-13.
Medical*Online
2) Itoh M, Ota K, Katsumata Y, et al. The eosinophilic leukocytosis of a heparin calcium treatment (the 2nd report). J Reprod Immunol. 2014 ; 106, 5.
 
3) Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010 ; 126 : 39-44.
 
4) Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012 ; 130 : 607-12.
PubMed
5) Gotlib J. World Health Organization-defined eosinophilic disorders : 2014 update on diagnosis, risk stratification, and management. Am J Hematol. 2014 ; 89 : 325-37.
PubMed
6) Gotlib J. World Health Organization-defined eosinophilic disorders : 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015 ; 90 : 1077-89.
PubMed
P.652 掲載の参考文献
1) Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009 ; 9 : 281-90.
 
2) Spaulding AR, Salgado-Pabon W, Kohler PL, et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013 ; 26 : 422-47.
 
3) Low DE. Toxic shock syndrome : major advances in pathogenesis, but not treatment. Crit Care Clin. 2013 ; 29 : 651-75.
 
4) Murray RJ. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J. 2005 ; 35 Suppl 2 : S106-19.
 
P.655 掲載の参考文献
1) Cone LA, Woodard DR, Schlievert PM, et al. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987 ; 317 : 146-9.
 
2) 清水可方, 五十嵐英夫, 村井貞子, 他. 本邦における劇症型A群 レンサ球菌感染症の現況と診断基準案の提示. 感染症誌. 1998 ; 72 : 258-65.
 
3) 国立感染症研究所. 発生動向調査年別報告数一覧 (全数把握) 五類感染症. <https://www.niid.go.jp/niid/ja/survei/2085-idwr/ydata/6563-report-ja2015-30.html>. Accessed July 11, 2017.
 
4) The working group on severe Streptococcal infections. Defining the group A Streptococcal toxic shock syndrome. JAMA. 1993 ; 269 : 390-1.
 
5) 池上淳, 沼田雅裕, 坂本育子, 他. 若年健康女性に発症した劇症型A群溶連菌感染症による原発性腹膜炎の1例. 産科と婦人科. 2015 ; 82 : 697-701.
 
6) Stevens DL. Streptococcal toxic-shock syndrome : spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995 ; 1 : 69-78.
 
P.659 掲載の参考文献
1) 非典型溶血性尿毒症症候群診断基準改定委員会, 日本腎臓学会, 日本小児科学会, 他. 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日腎会誌. 2016 ; 58 : 62-75.
 
2) Johnson S, Stojanovic J, Ariceta G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol. 2014 ; 29 : 1967-78.
 
3) 加藤秀樹, 吉田瑶子, 南学正臣. 補体・凝固関連aHUSの病態. 日腎会誌. 2014 ; 56 : 55-64.
 
P.662 掲載の参考文献
1) 山崎崇志, 増本純也, 上松一永. 家族性地中海熱の分子メカニズムと臨床像. 日本小児科学会雑誌. 2008 ; 9 : 1358-68.
 
2) 右田清志, 古賀智裕, 和泉泰衛, 他. 自己炎症性疾患-家族性地中海熱を中心に-. IRYO. 2009 ; 63 : 363-9.
 
3) 「家族性地中海熱の病態解明と治療指針の確立」研究班. 家族性地中海熱診療ガイドライン 2011. 厚生労働科学研究費補助金 難治性疾患克服研究事業. 2011.
 
4) 右田清志, 上松一永. 家族性地中海熱の臨床. Jpn J Clin Immunol. 2011 ; 34 : 355-60.
 
5) 山崎和子, 山崎崇志, 増本純也, 他. 自己炎症性疾患としての家族性地中海熱. 臨床病理. 2009 ; 57 : 371-81.
 
P.665 掲載の参考文献
1) Nokura K, Yamamoto H, Okawara Y, et al. Reversible limbic encephalitis caused by ovarian teratoma. Acta Neurol Scand. 1997 ; 95 : 367-73.
 
2) Okamura H, Oomori N, Uchitomi Y. An acutely confused 15-year old girl. Lancet. 1997 ; 350 : 488.
 
3) Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007 ; 61 : 25-36.
PubMed
4) Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011 ; 10 : 63-74.
 
5) Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis : an observational cohort study. Lancet Neurol. 2013 ; 12 : 157-65.
 
6) Suzuki S, Seki M, Suzuki N. Recent concept of limbic encephalitis : progress in anti-NMDA receptor encephalitis. Jpn J Clin Immunol. 2013 ; 36 : 86-94.
 
7) Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan. Long-term outcome without tumor removal. Neurology. 2008 ; 69 : 504-11.
 
8) Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encepjalitis : case series and analysis of the effect of antibodies. Lancer Neurol. 2008 ; 7 : 1091-8.
 
9) Iizuka T, Ishima D, Nishiyama K, et al. Clinical spectrum and treatment strategy in anti-NMDA receptor encephalitis : current status and issues. Clin Neurol. 2014 ; 54 : 1098-102.
 
P.667 掲載の参考文献
1) Alifano M, Trisolini R, Cancellieri A, et al. Thoracic endometriosis : current knowledge. Ann Thorac Surg. 2006 ; 81 : 761-9.
 
2) Lillington GA, Mitchell SP, Wood GA. Catamenial pneumothorax. JAMA. 1972 ; 219 : 1328-32.
 
3) Rossi NP, Goplerud CP. Recurrent catamenial pneumothorax. Arch Surg. 1974 ; 109 : 173-6.
 
4) Channabasavaiah AD, Joseph JV. Thoracic endometriosis : revisiting the association between clinical presentation and thoracic pathology based on thoracoscopic findings in 110 patient. Medicine. 2010 ; 89 : 183-8.
 
5) Bagan P, Le Pimpec Barthes F, Assouad J, et al. Catamenial pneumothorax : retrospective study of surgical treatment. Ann Thorac Surg. 2003 ; 75 : 378-81.
 
6) Aliafano M, Legras A, Rousset-Jablonski C, et al. Pneumothorax recurrence after surgery in women : clinicopathologic characteristics and management. Ann Thorac Surg. 2011 ; 92 : 322-7.
 

書評

最近チェックした商品履歴

Loading...